beta

ALXN

Alexion Pharmaceuticals Inc.

Alxn

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

10-24-2018 07-26-2018 04-26-2018 02-08-2018 10-26-2017 07-27-2017 04-27-2017
Actual EPS 1.86 1.88 1.53 1.28 1.28 1.31 1.2
Consensus EPS 1.59 1.49 1.29 1.09 1.13 1.08 1.05
Estimated EPS 1.59 1.49 1.29 1.09 1.13 1.08 1.05
Number of Estimates 7 8 8 9 1 7 9
EPS Surprise $0.27 $0.39 $0.24 $0.19 $0.15 $0.23 $0.15

Stats

Summary

Alexion Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.

Market Cap: 27.9 Billion

Primary Exchange: Nasdaq Global Select

Website: http://www.alexionpharm.com

Shares Outstanding: 223 Million

Float: 221 Million

Dividend: 0.0 (0.0%)

Beta: 1.218155

Sector: Healthcare

Industry: Biotechnology

Short Interest (Jan 12, 2018): 6.65 Million

Ethical Flags

Animal testing

Longest drawdown: 887 trading days

From: 2015-07-23 To: 2018-12-07

Lowest Point:

Comprehensive Positive Phase 3 Data for Alexion's ALXN1210 in Patients with Paroxysmal Nocturnal Hemoglobinuria Presented at American Society of Hematology (ASH) Annual Meeting and Published in Blood

via: Business Wire at 2018-12-03 14:32:00:000

- First Conference Presentation of Results for ALXN1210 in Patients on Soliris (Eculizumab) at ASH - - Publications in Blood of Results for ALXN1210 in Complement Inhibitor-Nave Patients and Patients on Soliris - - Presentation at ASH of New Results from Sensit… read more...

Comprehensive Positive Phase 3 Data for Alexion's ALXN1210 in Patients with Paroxysmal Nocturnal Hemoglobinuria Presented at American Society of Hematology (ASH) Annual Meeting and Published in Blood

via: Business Wire at 2018-12-03 14:32:00:000

- First Conference Presentation of Results for ALXN1210 in Patients on Soliris (Eculizumab) at ASH - - Publications in Blood of Results for ALXN1210 in Complement Inhibitor-Nave Patients and Patients on Soliris - - Presentation at ASH of New Results from Sensit… read more...

Comprehensive Positive Phase 3 Data for Alexion's ALXN1210 in Patients with Paroxysmal Nocturnal Hemoglobinuria Presented at American Society of Hematology (ASH) Annual Meeting and Published in Blood

via: Business Wire at 2018-12-03 14:32:00:000

- First Conference Presentation of Results for ALXN1210 in Patients on Soliris (Eculizumab) at ASH - - Publications in Blood of Results for ALXN1210 in Complement Inhibitor-Nave Patients and Patients on Soliris - - Presentation at ASH of New Results from Sensit… read more...

Akari announces new Coversin data, key readouts expected next quarter

via: SeekingAlpha at 2018-11-30 16:40:56:000

Thinly traded nano cap Akari Therapeutics (NASDAQ: AKTX ) announces new data on lead candidate Coversin that it says underscores its differentiation. More news on: Akari Therapeutics Plc, Alexion Pharmaceuticals, Inc., Healthcare stocks news, Read more … read more...

Akari announces new Coversin data, key readouts expected next quarter

via: SeekingAlpha at 2018-11-30 16:40:56:000

Thinly traded nano cap Akari Therapeutics (NASDAQ: AKTX ) announces new data on lead candidate Coversin that it says underscores its differentiation. More news on: Akari Therapeutics Plc, Alexion Pharmaceuticals, Inc., Healthcare stocks news, Read more … read more...

Akari announces new Coversin data, key readouts expected next quarter

via: SeekingAlpha at 2018-11-30 16:40:56:000

Thinly traded nano cap Akari Therapeutics (NASDAQ: AKTX ) announces new data on lead candidate Coversin that it says underscores its differentiation. More news on: Akari Therapeutics Plc, Alexion Pharmaceuticals, Inc., Healthcare stocks news, Read more … read more...

Eyes On Cyber Monday, Argentina And Mars (Stocks To Watch Podcast)

via: SeekingAlpha at 2018-11-25 08:08:53:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions, and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday, look f… read more...

Eyes On Cyber Monday, Argentina And Mars (Stocks To Watch Podcast)

via: SeekingAlpha at 2018-11-25 08:08:53:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions, and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday, look f… read more...

Eyes On Cyber Monday, Argentina And Mars (Stocks To Watch Podcast)

via: SeekingAlpha at 2018-11-25 08:08:53:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions, and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday, look f… read more...

Stocks To Watch: Eyes On Cyber Monday, Argentina And Mars

via: SeekingAlpha at 2018-11-24 09:03:18:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Investors will be looking for some soothing signs of global cooperation next week a… read more...

Alexion to Present at the Evercore ISI Healthcare Conference

via: Business Wire at 2018-11-20 16:30:00:000

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at Evercore ISIs Healthcare Conference in Boston, MA on Tuesday, November 27, 2018 at 8:45 a.m., ET. An audio webcast of the presentation will be available live. You can access the webcast at: ht… read more...

Alexion to Present at the Evercore ISI Healthcare Conference

via: Business Wire at 2018-11-20 16:30:00:000

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at Evercore ISIs Healthcare Conference in Boston, MA on Tuesday, November 27, 2018 at 8:45 a.m., ET. An audio webcast of the presentation will be available live. You can access the webcast at: ht… read more...

A Sluggish Start With Onpattro Is Not What Alnylam Shareholders Needed

via: SeekingAlpha at 2018-11-20 05:21:30:000

Theres not much any company can do about a bad tape, but Alnylam ( ALNY ) has seen sentiment sour pretty sharply since late 2017 despite the approval and launch of its first drug Onpattro. Between worries about greater competition (moreso from Pfizer ( PFE ) than Ionis ( IONS )/ … read more...

A Sluggish Start With Onpattro Is Not What Alnylam Shareholders Needed

via: SeekingAlpha at 2018-11-20 05:21:30:000

Theres not much any company can do about a bad tape, but Alnylam ( ALNY ) has seen sentiment sour pretty sharply since late 2017 despite the approval and launch of its first drug Onpattro. Between worries about greater competition (moreso from Pfizer ( PFE ) than Ionis ( IONS )/ … read more...

Omeros: Undervalued And Underloved, Shares Could Shine In 2019

via: SeekingAlpha at 2018-11-19 19:00:00:000

Omeros ( OMER ) may be one of the best kept secrets in biotech. The Seattle firm, with a market cap of approximately $640 million, has a marketed drug with $120 million in potential 2019 sales, a leading drug in multiple late-stage clinical trials with Orphan Drug Designation, as well as a dee… read more...

Omeros: Undervalued And Underloved, Shares Could Shine In 2019

via: SeekingAlpha at 2018-11-19 19:00:00:000

Omeros ( OMER ) may be one of the best kept secrets in biotech. The Seattle firm, with a market cap of approximately $640 million, has a marketed drug with $120 million in potential 2019 sales, a leading drug in multiple late-stage clinical trials with Orphan Drug Designation, as well as a dee… read more...

Omeros: Undervalued And Underloved, Shares Could Shine In 2019

via: SeekingAlpha at 2018-11-19 19:00:00:000

Omeros ( OMER ) may be one of the best kept secrets in biotech. The Seattle firm, with a market cap of approximately $640 million, has a marketed drug with $120 million in potential 2019 sales, a leading drug in multiple late-stage clinical trials with Orphan Drug Designation, as well as a dee… read more...

Biotechs getting slammed again, XBI down almost 4%

via: SeekingAlpha at 2018-11-12 11:45:16:000

In an all-too-frequent narrative, biotechs are getting roughed up yet again. The SPDR S&P Biotech ETF ( XBI -3.5% ) is in the red, albeit on below-average volume. The ETF has lost ~22% of its value in a little over two months. More news on: SPDR Biotech ETF, Ionis Pharmaceuticals, In… read more...

Biotechs getting slammed again, XBI down almost 4%

via: SeekingAlpha at 2018-11-12 11:45:16:000

In an all-too-frequent narrative, biotechs are getting roughed up yet again. The SPDR S&P Biotech ETF ( XBI -3.5% ) is in the red, albeit on below-average volume. The ETF has lost ~22% of its value in a little over two months. More news on: SPDR Biotech ETF, Ionis Pharmaceuticals, In… read more...

Biotechs getting slammed again, XBI down almost 4%

via: SeekingAlpha at 2018-11-12 11:45:16:000

In an all-too-frequent narrative, biotechs are getting roughed up yet again. The SPDR S&P Biotech ETF ( XBI -3.5% ) is in the red, albeit on below-average volume. The ETF has lost ~22% of its value in a little over two months. More news on: SPDR Biotech ETF, Ionis Pharmaceuticals, In… read more...

Biotechs getting slammed again, XBI down almost 4%

via: SeekingAlpha at 2018-11-12 11:45:16:000

In an all-too-frequent narrative, biotechs are getting roughed up yet again. The SPDR S&P Biotech ETF ( XBI -3.5% ) is in the red, albeit on below-average volume. The ETF has lost ~22% of its value in a little over two months. More news on: SPDR Biotech ETF, Ionis Pharmaceuticals, In… read more...

Alexion to Present at Credit Suisse's 27th Annual Healthcare Conference

via: Business Wire at 2018-11-07 16:30:00:000

Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that management will present at Credit Suisses 27 th Annual Healthcare Conference in Scottsdale, AZ on Tuesday, November 13, 2018 at 10:00 a.m., ET. An audio webcast of the presentation will be available live. You can access … read more...

Alexion to Present at Credit Suisse's 27th Annual Healthcare Conference

via: Business Wire at 2018-11-07 16:30:00:000

Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that management will present at Credit Suisses 27 th Annual Healthcare Conference in Scottsdale, AZ on Tuesday, November 13, 2018 at 10:00 a.m., ET. An audio webcast of the presentation will be available live. You can access … read more...

Alexion to Present at Credit Suisse's 27th Annual Healthcare Conference

via: Business Wire at 2018-11-07 16:30:00:000

Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that management will present at Credit Suisses 27 th Annual Healthcare Conference in Scottsdale, AZ on Tuesday, November 13, 2018 at 10:00 a.m., ET. An audio webcast of the presentation will be available live. You can access … read more...

Alexion Completes Acquisition of Syntimmune

via: Business Wire at 2018-11-02 11:05:00:000

- Acquisition adds clinical-stage anti-FcRn antibody SYNT001 to companys growing pipeline - - SYNT001 is first and only anti-FcRn asset currently in clinical development for warm autoimmune hemolytic anemia (WAIHA) - Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today ann… read more...

Alexion Completes Acquisition of Syntimmune

via: Business Wire at 2018-11-02 11:05:00:000

- Acquisition adds clinical-stage anti-FcRn antibody SYNT001 to companys growing pipeline - - SYNT001 is first and only anti-FcRn asset currently in clinical development for warm autoimmune hemolytic anemia (WAIHA) - Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today ann… read more...

Alexion Completes Acquisition of Syntimmune

via: Business Wire at 2018-11-02 11:05:00:000

- Acquisition adds clinical-stage anti-FcRn antibody SYNT001 to companys growing pipeline - - SYNT001 is first and only anti-FcRn asset currently in clinical development for warm autoimmune hemolytic anemia (WAIHA) - Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today ann… read more...

Alexion Completes Acquisition of Syntimmune

via: Business Wire at 2018-11-02 11:05:00:000

- Acquisition adds clinical-stage anti-FcRn antibody SYNT001 to companys growing pipeline - - SYNT001 is first and only anti-FcRn asset currently in clinical development for warm autoimmune hemolytic anemia (WAIHA) - Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today ann… read more...

Alexion Completes Acquisition of Syntimmune

via: Business Wire at 2018-11-02 11:05:00:000

- Acquisition adds clinical-stage anti-FcRn antibody SYNT001 to companys growing pipeline - - SYNT001 is first and only anti-FcRn asset currently in clinical development for warm autoimmune hemolytic anemia (WAIHA) - Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today ann… read more...

Alexion Announces Upcoming Data Presentations at American Society of Hematology Annual Meeting

via: Business Wire at 2018-11-01 10:23:00:000

- Nine abstracts accepted, including three oral presentations of ALXN1210 Phase 3 PNH data - Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that nine abstracts from its complement research and development program have been accepted for presentation at the American Socie… read more...

Alexion Pharmaceuticals: An Impressive Rare Disease Player At The End Of 2018

via: SeekingAlpha at 2018-10-31 19:13:27:000

The year 2018 may be ending for Alexion Pharmaceuticals ( ALXN ) at a high note. Not only did the company manage to beat both revenue and EPS estimates in Q3 2018 , but Alexion Pharmaceuticals also raised its full-year 2018 revenue guidance from previously projected $3.98-4.01 billion to $4.0… read more...

Dicerna Pharmaceuticals Keeps The Deals Rolling In On The Promise Of Its Groundbreaking GalXC RNAi Technology

via: SeekingAlpha at 2018-10-30 09:54:50:000

Recently, Dicerna Pharmaceuticals ( DRNA ) announced a partnership with Eli Lilly ( LLY ) which amounts to an upfront payment and an equity stake . This is just one of the most recent validations of Dicerna's GalXC technology. Just this past week, Dicerna garnered another deal with Ale… read more...

Dicerna Pharmaceuticals Keeps The Deals Rolling In On The Promise Of Its Groundbreaking GalXC RNAi Technology

via: SeekingAlpha at 2018-10-30 09:54:50:000

Recently, Dicerna Pharmaceuticals ( DRNA ) announced a partnership with Eli Lilly ( LLY ) which amounts to an upfront payment and an equity stake . This is just one of the most recent validations of Dicerna's GalXC technology. Just this past week, Dicerna garnered another deal with Ale… read more...

Trump mulling tieing U.S. drug prices to Europe's

via: SeekingAlpha at 2018-10-26 08:08:52:000

U.S. drug makers are facing a down day today after President Trump announced his first potential tactic aimed at lowering drug prices. Specifically, he is exploring benchmarking Medicare reimbursement to the average price in Europe for drugs administered by doctors, a group of medicines do… read more...

Trump mulling tieing U.S. drug prices to Europe's

via: SeekingAlpha at 2018-10-26 08:08:52:000

U.S. drug makers are facing a down day today after President Trump announced his first potential tactic aimed at lowering drug prices. Specifically, he is exploring benchmarking Medicare reimbursement to the average price in Europe for drugs administered by doctors, a group of medicines do… read more...

Trump mulling tieing U.S. drug prices to Europe's

via: SeekingAlpha at 2018-10-26 08:08:52:000

U.S. drug makers are facing a down day today after President Trump announced his first potential tactic aimed at lowering drug prices. Specifically, he is exploring benchmarking Medicare reimbursement to the average price in Europe for drugs administered by doctors, a group of medicines do… read more...

Trump mulling tieing U.S. drug prices to Europe's

via: SeekingAlpha at 2018-10-26 08:08:52:000

U.S. drug makers are facing a down day today after President Trump announced his first potential tactic aimed at lowering drug prices. Specifically, he is exploring benchmarking Medicare reimbursement to the average price in Europe for drugs administered by doctors, a group of medicines do… read more...

Alexion Pharmaceuticals (ALXN) Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-10-24 14:10:49:000

Alexion Pharmaceuticals, Inc. (ALXN) Q3 2018 Earnings Call October 24, 2018 8:00 am ET Executives Susan Altschuller - Alexion Pharmaceuticals, Inc. Ludwig N. Hantson - Alexion Pharmaceuticals, Inc. Paul J. Clancy - Alexion Pharmaceuticals, Inc. John J. Orloff - Alexion Pharmace… read more...

Alexion Pharmaceuticals (ALXN) Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-10-24 14:10:49:000

Alexion Pharmaceuticals, Inc. (ALXN) Q3 2018 Earnings Call October 24, 2018 8:00 am ET Executives Susan Altschuller - Alexion Pharmaceuticals, Inc. Ludwig N. Hantson - Alexion Pharmaceuticals, Inc. Paul J. Clancy - Alexion Pharmaceuticals, Inc. John J. Orloff - Alexion Pharmace… read more...

Alexion Pharmaceuticals, Inc. 2018 Q3 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-10-24 10:06:34:000

The following slide deck was published by Alexion Pharmaceuticals, Inc. in conjunction with their 2018 Q3 earnings Read more … read more...

Alexion Pharmaceuticals, Inc. 2018 Q3 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-10-24 10:06:34:000

The following slide deck was published by Alexion Pharmaceuticals, Inc. in conjunction with their 2018 Q3 earnings Read more … read more...

Alexion up 4% premarket on Dicerna deal

via: SeekingAlpha at 2018-10-24 09:16:15:000

Alexion Pharmaceuticals (NASDAQ: ALXN ) is up 4% premarket on modest volume on the heels of its collaboration with Dicerna Pharmaceuticals (NASDAQ: DRNA ) aimed at developing RNAi therapies for complement-mediated diseases. More news on: Alexion Pharmaceuticals, Inc., Dicerna… read more...

Alexion up 4% premarket on Dicerna deal

via: SeekingAlpha at 2018-10-24 09:16:15:000

Alexion Pharmaceuticals (NASDAQ: ALXN ) is up 4% premarket on modest volume on the heels of its collaboration with Dicerna Pharmaceuticals (NASDAQ: DRNA ) aimed at developing RNAi therapies for complement-mediated diseases. More news on: Alexion Pharmaceuticals, Inc., Dicerna… read more...

Alexion Pharmaceuticals Q3 top line up 20%; non-GAAP EPS up 40%; raises revenue and non-GAAP EPS guidance

via: SeekingAlpha at 2018-10-24 07:53:09:000

Alexion Pharmaceuticals ( ALXN ) Q3 results: Revenues: $1,026.5M (+19.5%). More news on: Alexion Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more … read more...

Alexion Pharmaceuticals Q3 top line up 20%; non-GAAP EPS up 40%; raises revenue and non-GAAP EPS guidance

via: SeekingAlpha at 2018-10-24 07:53:09:000

Alexion Pharmaceuticals ( ALXN ) Q3 results: Revenues: $1,026.5M (+19.5%). More news on: Alexion Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more … read more...

Alexion Pharmaceuticals beats by $0.28, beats on revenue

via: SeekingAlpha at 2018-10-24 06:37:50:000

Alexion Pharmaceuticals (NASDAQ: ALXN ): Q3 Non-GAAP EPS of $2.02 beats by $0.28 ; GAAP EPS of $1.47 beats by $0.24 . More news on: Alexion Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Alexion Pharmaceuticals beats by $0.28, beats on revenue

via: SeekingAlpha at 2018-10-24 06:37:50:000

Alexion Pharmaceuticals (NASDAQ: ALXN ): Q3 Non-GAAP EPS of $2.02 beats by $0.28 ; GAAP EPS of $1.47 beats by $0.24 . More news on: Alexion Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Alexion Reports Third Quarter 2018 Results

via: Business Wire at 2018-10-24 06:35:00:000

3Q18 total revenues of $1,026.5 million, a 20 percent increase over 3Q17 and a 26 percent volume increase 3Q18 GAAP diluted EPS of $1.47 per share; non-GAAP diluted EPS of $2.02 per share Updated 2018 full-year guidance given the strength of the business Positive topline Phase … read more...

Alexion Reports Third Quarter 2018 Results

via: Business Wire at 2018-10-24 06:35:00:000

3Q18 total revenues of $1,026.5 million, a 20 percent increase over 3Q17 and a 26 percent volume increase 3Q18 GAAP diluted EPS of $1.47 per share; non-GAAP diluted EPS of $2.02 per share Updated 2018 full-year guidance given the strength of the business Positive topline Phase … read more...

Alexion and Dicerna Announce Collaboration to Discover and Develop RNAi Therapies for Complement-Mediated Diseases

via: Business Wire at 2018-10-24 06:30:00:000

- Collaboration provides opportunity to build on Alexions more than two decades of complement leadership with expansion into RNAi-based therapies using Dicernas GalXC technology - - Agreement provides Alexion with exclusive worldwide licenses as well as developm… read more...

Alexion and Dicerna Announce Collaboration to Discover and Develop RNAi Therapies for Complement-Mediated Diseases

via: Business Wire at 2018-10-24 06:30:00:000

- Collaboration provides opportunity to build on Alexions more than two decades of complement leadership with expansion into RNAi-based therapies using Dicernas GalXC technology - - Agreement provides Alexion with exclusive worldwide licenses as well as developm… read more...

Notable earnings before Wednesday's open

via: SeekingAlpha at 2018-10-23 17:30:34:000

AB , ALXN , APH , AVX , BA , BABY , BCO , BKU , BOKF , BPOP , BSX , CHKP , CRS , DTE , EVR , FCX , FSV , GD , GRA , HLT , IR , ITW , LAD , LH , MHO , MKTX , NDAQ , NOC , NSC , NYCB , OC , PB , POL , QSR , RES , ROL , SCHN , SCL , SIRI , SLAB , SLGN ,… read more...

Biotechs set for down gap at open

via: SeekingAlpha at 2018-10-23 09:25:19:000

The SPDR S&P Biotech ETF (NYSEARCA: XBI ) is down 2% premarket on light volume, continuing its 2% slide yesterday. More news on: SPDR Biotech ETF, Amgen Inc., Biogen Inc., Healthcare stocks news, Stocks on the move, News on ETFs, Read more … read more...

Marker Therapeutics: A Safer And Potentially More Effective CAR-T Alternative

via: SeekingAlpha at 2018-10-18 08:49:27:000

Marker Therapeutics, is an immunotherapy innovator bringing an antigen-sensitized T cell product to market in a number of different cancer indications. The company is the product of a merger between TapImmune and Marker Therapeutics that completed on Oct 17th, 2018 and on Thursday, October 1… read more...

Marker Therapeutics: A Safer And Potentially More Effective CAR-T Alternative

via: SeekingAlpha at 2018-10-18 08:49:27:000

Marker Therapeutics, is an immunotherapy innovator bringing an antigen-sensitized T cell product to market in a number of different cancer indications. The company is the product of a merger between TapImmune and Marker Therapeutics that completed on Oct 17th, 2018 and on Thursday, October 1… read more...

Marker Therapeutics: A Safer And Potentially More Effective CAR-T Alternative

via: SeekingAlpha at 2018-10-18 08:49:27:000

Marker Therapeutics, is an immunotherapy innovator bringing an antigen-sensitized T cell product to market in a number of different cancer indications. The company is the product of a merger between TapImmune and Marker Therapeutics that completed on Oct 17th, 2018 and on Thursday, October 1… read more...

Invesco S&P 500 Equal Weight ETF (RSP) September Summary

via: SeekingAlpha at 2018-10-09 11:15:45:000

September monthly performance was: +0.12% More news on: Invesco S&P 500 Equal Weight ETF, Edwards Lifesciences Corp, Alexion Pharmaceuticals, Inc., , Read more … read more...

Invesco S&P 500 Equal Weight ETF (RSP) September Summary

via: SeekingAlpha at 2018-10-09 11:15:45:000

September monthly performance was: +0.12% More news on: Invesco S&P 500 Equal Weight ETF, Edwards Lifesciences Corp, Alexion Pharmaceuticals, Inc., , Read more … read more...

Invesco S&P 500 Equal Weight ETF (RSP) September Summary

via: SeekingAlpha at 2018-10-09 11:15:45:000

September monthly performance was: +0.12% More news on: Invesco S&P 500 Equal Weight ETF, Edwards Lifesciences Corp, Alexion Pharmaceuticals, Inc., , Read more … read more...

Invesco S&P 500 Equal Weight ETF (RSP) September Summary

via: SeekingAlpha at 2018-10-09 11:15:45:000

September monthly performance was: +0.12% More news on: Invesco S&P 500 Equal Weight ETF, Edwards Lifesciences Corp, Alexion Pharmaceuticals, Inc., , Read more … read more...

The Biotech Conundrum

via: SeekingAlpha at 2018-10-05 14:21:58:000

As the S&P 500 ( SPY ) and the Dow Jones ( DIA ) indexes recorded new highs last month, other indexes were consolidating and drifting lower. The Nasdaq ( QQQ ) retreated a little less than -1%, after being down nearly -3% during the month. The small-cap index, Russell 2000 ( IWM ), held up… read more...

The Biotech Conundrum

via: SeekingAlpha at 2018-10-05 14:21:58:000

As the S&P 500 ( SPY ) and the Dow Jones ( DIA ) indexes recorded new highs last month, other indexes were consolidating and drifting lower. The Nasdaq ( QQQ ) retreated a little less than -1%, after being down nearly -3% during the month. The small-cap index, Russell 2000 ( IWM ), held up… read more...

The Biotech Conundrum

via: SeekingAlpha at 2018-10-05 14:21:58:000

As the S&P 500 ( SPY ) and the Dow Jones ( DIA ) indexes recorded new highs last month, other indexes were consolidating and drifting lower. The Nasdaq ( QQQ ) retreated a little less than -1%, after being down nearly -3% during the month. The small-cap index, Russell 2000 ( IWM ), held up… read more...

The Biotech Conundrum

via: SeekingAlpha at 2018-10-05 14:21:58:000

As the S&P 500 ( SPY ) and the Dow Jones ( DIA ) indexes recorded new highs last month, other indexes were consolidating and drifting lower. The Nasdaq ( QQQ ) retreated a little less than -1%, after being down nearly -3% during the month. The small-cap index, Russell 2000 ( IWM ), held up… read more...

Alexion to Report Third Quarter 2018 Results on Wednesday, October 24, 2018

via: Business Wire at 2018-10-04 16:30:00:000

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the third quarter ended September 30, 2018 before the US financial markets open on October 24, 2018. Following the release of the financial results, Alexion management will con… read more...

Healthcare And Biotechnology Dashboard - Update

via: SeekingAlpha at 2018-10-03 05:23:09:000

This article series provides a monthly dashboard of industries in each sector of the GICS classification. It compares valuation and quality factors relative to their historical averages. Executive summary Biotechnology is undervalued with regards to historical averages in 2 out of 3 valu… read more...

Best And Worst-Performing Stocks In The S&P 500 Over The Last 20 Years And How They Have Performed In 2018

via: SeekingAlpha at 2018-09-27 09:32:18:000

Background Twenty years ago, on August 17th, 1998 to be precise, a financial crisis hit Russia ( RSX , ERUS ). It resulted in the Russian government and the Russian Central Bank devaluing the ruble and defaulting on its debt. The Russian crisis of 1998 happened only one year after the Asi… read more...

Best And Worst-Performing Stocks In The S&P 500 Over The Last 20 Years And How They Have Performed In 2018

via: SeekingAlpha at 2018-09-27 09:32:18:000

Background Twenty years ago, on August 17th, 1998 to be precise, a financial crisis hit Russia ( RSX , ERUS ). It resulted in the Russian government and the Russian Central Bank devaluing the ruble and defaulting on its debt. The Russian crisis of 1998 happened only one year after the Asi… read more...

Best And Worst-Performing Stocks In The S&P 500 Over The Last 20 Years And How They Have Performed In 2018

via: SeekingAlpha at 2018-09-27 09:32:18:000

Background Twenty years ago, on August 17th, 1998 to be precise, a financial crisis hit Russia ( RSX , ERUS ). It resulted in the Russian government and the Russian Central Bank devaluing the ruble and defaulting on its debt. The Russian crisis of 1998 happened only one year after the Asi… read more...

Alexion Pharmaceuticals, Inc. (ALXN) CEO Ludwig Hantson on Acquisition of Syntimmune Conference Call (Transcript)

via: SeekingAlpha at 2018-09-26 16:34:07:000

Alexion Pharmaceuticals, Inc. (ALXN) Alexion to Acquire Syntimmune Conference Call September 26, 2018 8:00 AM ET Executives Susan Altschuller - Vice President, Investor Relations Ludwig Hantson - Chief Executive Officer John Orloff - Head of R&D Paul Clancy - Chief Financia… read more...

Biotech Analysis Central Pharma News: Gilead's New Move, Sarepta's Hold Removal, Alexion's Plan

via: SeekingAlpha at 2018-09-26 16:30:30:000

Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Gilead Sciences Implements Generic Hepatitis C Franchise To Boost Sales News: Recently, Gilead Sciences ( GILD ) announced that it will be pushing to … read more...

Alexion Pharmaceuticals (ALXN) To Acquire Syntimmune For $1.2B - Slideshow

via: SeekingAlpha at 2018-09-26 12:39:03:000

The following slide deck was published by Alexion Pharmaceuticals, Inc. in conjunction with this Read more … read more...

Ra Pharma's zilucoplan shows favorable PK profile in renal impairment patients, expanding potential clinical programs

via: SeekingAlpha at 2018-09-26 08:14:53:000

Results from a Phase 1b assessing the pharmacokinetics of Ra Pharmaceuticals' (NASDAQ: RARX ) RA101495 SC (zilucoplan) in patients with severe renal impairment showed a similar profile compared to healthy patients. There were no adverse events reported and the data indicate that no adjust… read more...

Alexion to acquire Syntimmune

via: SeekingAlpha at 2018-09-26 07:21:24:000

Alexion Pharmaceuticals(NASDAQ: ALXN ) will acquire Syntimmune, a clinical-stage biotechnology company developing antibody therapeutics targeting the neonatal Fc receptor (FcRn). More news on: Alexion Pharmaceuticals, Inc., Healthcare stocks news, Read more … read more...

Alexion to Acquire Syntimmune

via: Business Wire at 2018-09-26 06:30:00:000

- Brings in clinical-stage anti-FcRn antibody SYNT001 with potential to address a number of rare IgG-mediated diseases - - SYNT001 is first and only anti-FcRn asset currently in clinical development for warm autoimmune hemolytic anemia (WAIHA) - - Conference call and webcast sched… read more...

Alexion to Present at the Leerink Partners Roundtable Series: Rare Disease & Oncology

via: Business Wire at 2018-09-25 16:30:00:000

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at the Leerink Partners Roundtable Series: Rare Disease & Oncology in New York, NY on Tuesday, October 2, 2018 at 10 a.m., EDT. An audio webcast of the presentation will be available live. You can acc… read more...

Premarket Gainers as of 9:05 am (09/24/2018)

via: SeekingAlpha at 2018-09-24 09:20:17:000

AMRN +280% on positive results from REDUCE-IT study. More news on: Amarin Corporation PLC, AzurRX Biopharma, Applied Genetic Technologies Corporation, Stocks on the move, , Top stock market news, Read more … read more...

Stocks making the biggest move premarket: CMCSA, FOXA, P, SIRI, ALXN & more

via: CNBC at 2018-09-24 07:45:00:000

No summary available. read more...

Alexion's Soliris shows treatment effect in late-stage rare CNS disorder; shares up 5% premarket

via: SeekingAlpha at 2018-09-24 07:29:28:000

Alexion Pharmaceuticals (NASDAQ: ALXN ) is up 5% premarket on light volume on the heels of its announcement of positive results from a Phase 3 clinical trial, PREVENT , evaluating Soliris (eculizumab) in patients with a rare complement-mediated central nervous system (CNS) dis… read more...

Alexion Announces Successful Phase 3 PREVENT Study of Soliris® (Eculizumab) in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)

via: Business Wire at 2018-09-24 06:30:00:000

-- Soliris Reduced the Risk of Adjudicated On-Trial Relapse by 94.2% Compared to Placebo (p < 0.0001) -- -- Safety Profile Consistent with that Seen in Previous Studies and Real-World Use -- -- Preparing for Regulatory Submissions in the US, European Union, and Japa… read more...

Your Daily Scoop: Recro Proceeds, MannKind Zooms, Aduro's Publication

via: SeekingAlpha at 2018-09-07 16:31:01:000

News in focus: REPH, MNKD Recro Pharma plans to resubmit NDA Discussion : On September 4, Recro Pharma ( REPH ) reported positive outcome of its meeting with the FDA regarding its NDA for IV meloxicam that was rejected in last May. Based on the discussion with the FDA, the comp… read more...

Your Daily Scoop: Recro Proceeds, MannKind Zooms, Aduro's Publication

via: SeekingAlpha at 2018-09-07 16:31:01:000

News in focus: REPH, MNKD Recro Pharma plans to resubmit NDA Discussion : On September 4, Recro Pharma ( REPH ) reported positive outcome of its meeting with the FDA regarding its NDA for IV meloxicam that was rejected in last May. Based on the discussion with the FDA, the comp… read more...

Your Daily Scoop: Recro Proceeds, MannKind Zooms, Aduro's Publication

via: SeekingAlpha at 2018-09-07 16:31:01:000

News in focus: REPH, MNKD Recro Pharma plans to resubmit NDA Discussion : On September 4, Recro Pharma ( REPH ) reported positive outcome of its meeting with the FDA regarding its NDA for IV meloxicam that was rejected in last May. Based on the discussion with the FDA, the comp… read more...

Your Daily Scoop: Recro Proceeds, MannKind Zooms, Aduro's Publication

via: SeekingAlpha at 2018-09-07 16:31:01:000

News in focus: REPH, MNKD Recro Pharma plans to resubmit NDA Discussion : On September 4, Recro Pharma ( REPH ) reported positive outcome of its meeting with the FDA regarding its NDA for IV meloxicam that was rejected in last May. Based on the discussion with the FDA, the comp… read more...

Your Daily Scoop: Recro Proceeds, MannKind Zooms, Aduro's Publication

via: SeekingAlpha at 2018-09-07 16:31:01:000

News in focus: REPH, MNKD Recro Pharma plans to resubmit NDA Discussion : On September 4, Recro Pharma ( REPH ) reported positive outcome of its meeting with the FDA regarding its NDA for IV meloxicam that was rejected in last May. Based on the discussion with the FDA, the comp… read more...

Alexion to Present at Morgan Stanley's 16th Annual Global Healthcare Conference

via: Business Wire at 2018-09-07 16:30:00:000

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at Morgan Stanleys 16 th Annual Global Healthcare Conference in New York, NY on Friday, September 14, 2018 at 11:05 a.m., EDT. An audio webcast of the presentation will be available live. You can… read more...

Alexion to Present at Morgan Stanley's 16th Annual Global Healthcare Conference

via: Business Wire at 2018-09-07 16:30:00:000

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at Morgan Stanleys 16 th Annual Global Healthcare Conference in New York, NY on Friday, September 14, 2018 at 11:05 a.m., EDT. An audio webcast of the presentation will be available live. You can… read more...

Alexion to Present at Morgan Stanley's 16th Annual Global Healthcare Conference

via: Business Wire at 2018-09-07 16:30:00:000

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at Morgan Stanleys 16 th Annual Global Healthcare Conference in New York, NY on Friday, September 14, 2018 at 11:05 a.m., EDT. An audio webcast of the presentation will be available live. You can… read more...

Alexion to Present at Morgan Stanley's 16th Annual Global Healthcare Conference

via: Business Wire at 2018-09-07 16:30:00:000

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at Morgan Stanleys 16 th Annual Global Healthcare Conference in New York, NY on Friday, September 14, 2018 at 11:05 a.m., EDT. An audio webcast of the presentation will be available live. You can… read more...

Alexion to Present at Morgan Stanley's 16th Annual Global Healthcare Conference

via: Business Wire at 2018-09-07 16:30:00:000

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at Morgan Stanleys 16 th Annual Global Healthcare Conference in New York, NY on Friday, September 14, 2018 at 11:05 a.m., EDT. An audio webcast of the presentation will be available live. You can… read more...

Apellis Pharma up 3% on encouraging APL-2 data

via: SeekingAlpha at 2018-09-04 13:53:17:000

Apellis Pharmaceuticals ( APLS +2.5% ) is up on below-average volume on the heels of its update on a Phase 1b clinical trial, PHAROAH , evaluating APL-2 in patients with paroxysmal nocturnal hemoglobinuria (PNH) on Alexion Pharmaceuticals' ( ALXN -2.5% ) Soliris (eculizumab) who are sev… read more...

Apellis Pharma up 3% on encouraging APL-2 data

via: SeekingAlpha at 2018-09-04 13:53:17:000

Apellis Pharmaceuticals ( APLS +2.5% ) is up on below-average volume on the heels of its update on a Phase 1b clinical trial, PHAROAH , evaluating APL-2 in patients with paroxysmal nocturnal hemoglobinuria (PNH) on Alexion Pharmaceuticals' ( ALXN -2.5% ) Soliris (eculizumab) who are sev… read more...

Apellis Pharma up 3% on encouraging APL-2 data

via: SeekingAlpha at 2018-09-04 13:53:17:000

Apellis Pharmaceuticals ( APLS +2.5% ) is up on below-average volume on the heels of its update on a Phase 1b clinical trial, PHAROAH , evaluating APL-2 in patients with paroxysmal nocturnal hemoglobinuria (PNH) on Alexion Pharmaceuticals' ( ALXN -2.5% ) Soliris (eculizumab) who are sev… read more...

Alexion to Present at Citi's 13th Annual Biotech Conference

via: Business Wire at 2018-08-29 16:30:00:000

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at Citis 13 th Annual Biotech Conference in Boston, MA on Thursday, September 6, 2018 at 8:15 a.m., EDT. An audio webcast of the presentation will be available live. You can access the webcast at… read more...

Alexion to Present at Citi's 13th Annual Biotech Conference

via: Business Wire at 2018-08-29 16:30:00:000

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at Citis 13 th Annual Biotech Conference in Boston, MA on Thursday, September 6, 2018 at 8:15 a.m., EDT. An audio webcast of the presentation will be available live. You can access the webcast at… read more...

Alexion to Present at Citi's 13th Annual Biotech Conference

via: Business Wire at 2018-08-29 16:30:00:000

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at Citis 13 th Annual Biotech Conference in Boston, MA on Thursday, September 6, 2018 at 8:15 a.m., EDT. An audio webcast of the presentation will be available live. You can access the webcast at… read more...

Money flow stays positive in biotechs, XBI up 6% since last week

via: SeekingAlpha at 2018-08-27 11:39:49:000

Biotechs continue their modest rally. The SPDR S&P Biotech ETF ( XBI +1.9% ) is up albeit on below average. It has jumped 6% since last week. More news on: SPDR Biotech ETF, Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the … read more...

Money flow stays positive in biotechs, XBI up 6% since last week

via: SeekingAlpha at 2018-08-27 11:39:49:000

Biotechs continue their modest rally. The SPDR S&P Biotech ETF ( XBI +1.9% ) is up albeit on below average. It has jumped 6% since last week. More news on: SPDR Biotech ETF, Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the … read more...

FDA accepts priority review of ALXN1210 as a treatment for patients with PNH in the US

via: SeekingAlpha at 2018-08-20 07:00:54:000

The FDA has accepted for review Alexion Pharmaceuticals' (NASDAQ: ALXN ) Biologics License Application (BLA) for approval of ALXN1210, the Companys investigational long-acting C5 complement inhibitor, for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). M… read more...

FDA accepts priority review of ALXN1210 as a treatment for patients with PNH in the US

via: SeekingAlpha at 2018-08-20 07:00:54:000

The FDA has accepted for review Alexion Pharmaceuticals' (NASDAQ: ALXN ) Biologics License Application (BLA) for approval of ALXN1210, the Companys investigational long-acting C5 complement inhibitor, for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). M… read more...

FDA accepts priority review of ALXN1210 as a treatment for patients with PNH in the US

via: SeekingAlpha at 2018-08-20 07:00:54:000

The FDA has accepted for review Alexion Pharmaceuticals' (NASDAQ: ALXN ) Biologics License Application (BLA) for approval of ALXN1210, the Companys investigational long-acting C5 complement inhibitor, for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). M… read more...

FDA Accepts Priority Review of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) in the US

via: Business Wire at 2018-08-20 06:30:00:000

-- EU Filing Accepted and Under Review -- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the Companys Biologics License Application (BLA) for approval of ALXN1210, the Companys invest… read more...

FDA Accepts Priority Review of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) in the US

via: Business Wire at 2018-08-20 06:30:00:000

-- EU Filing Accepted and Under Review -- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the Companys Biologics License Application (BLA) for approval of ALXN1210, the Companys invest… read more...

FDA Accepts Priority Review of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) in the US

via: Business Wire at 2018-08-20 06:30:00:000

-- EU Filing Accepted and Under Review -- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the Companys Biologics License Application (BLA) for approval of ALXN1210, the Companys invest… read more...

Walmart Has Become A Must-Own Stock - Cramer's Mad Money (8/16/18)

via: SeekingAlpha at 2018-08-17 08:25:33:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday , August 16. The market rally on Thursday will last a lot longer than the bears think. There was positivity in the market after resumed trade talks with China. Cramer said that low profile talks a… read more...

Walmart Has Become A Must-Own Stock - Cramer's Mad Money (8/16/18)

via: SeekingAlpha at 2018-08-17 08:25:33:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday , August 16. The market rally on Thursday will last a lot longer than the bears think. There was positivity in the market after resumed trade talks with China. Cramer said that low profile talks a… read more...

Walmart Has Become A Must-Own Stock - Cramer's Mad Money (8/16/18)

via: SeekingAlpha at 2018-08-17 08:25:33:000

Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Thursday , August 16. The market rally on Thursday will last a lot longer than the bears think. There was positivity in the market after resumed trade talks with China. Cramer said that low profile talks a… read more...

Alexion: Priced Right For Long-Term Investors

via: SeekingAlpha at 2018-08-16 18:41:27:000

If you look at a typical brokerage summary page for Alexion Pharmaceuticals ( ALXN ), one thing you might spot is negative earnings for the past year and a negative P/E (price to earnings) ratio. Clinical development stage biotechs often run for years at a loss, generating such figures, but Al… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-08-07 07:50:38:000

ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Hold rating and $17 (22% upside) price target at Stifel. More news on: ACADIA Pharmaceuticals Inc., Alder Biopharmaceuticals Inc., Alkermes plc, Healthcare stocks news, Stocks on the move, , Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-08-07 07:50:38:000

ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Hold rating and $17 (22% upside) price target at Stifel. More news on: ACADIA Pharmaceuticals Inc., Alder Biopharmaceuticals Inc., Alkermes plc, Healthcare stocks news, Stocks on the move, , Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-08-07 07:50:38:000

ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Hold rating and $17 (22% upside) price target at Stifel. More news on: ACADIA Pharmaceuticals Inc., Alder Biopharmaceuticals Inc., Alkermes plc, Healthcare stocks news, Stocks on the move, , Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-08-07 07:50:38:000

ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Hold rating and $17 (22% upside) price target at Stifel. More news on: ACADIA Pharmaceuticals Inc., Alder Biopharmaceuticals Inc., Alkermes plc, Healthcare stocks news, Stocks on the move, , Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-08-07 07:50:38:000

ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Hold rating and $17 (22% upside) price target at Stifel. More news on: ACADIA Pharmaceuticals Inc., Alder Biopharmaceuticals Inc., Alkermes plc, Healthcare stocks news, Stocks on the move, , Read more … read more...

Alexion: Finding Success By Improving Lives

via: SeekingAlpha at 2018-08-06 02:01:37:000

When you're feeling like investing with your conscience, a company like Alexion Pharmaceuticals ( ALXN ) can give you that warm and fuzzy feeling. Alexion develops treatments for rare diseases where no other treatment is available. As a conscientious investor, you can feel great about how Al… read more...

Ra Pharmaceuticals: Is Trying To Copy What Works A Good Product Development Strategy?

via: SeekingAlpha at 2018-07-30 19:43:40:000

Ive been following Ra Pharmaceuticals ( RARX ) to some extent over the last few years due to my interest in rare diseases and the complement space. After discussing the company and its approach with one of our valued Growth Stock Forum members in the chat room, I decided to take a de… read more...

Ra Pharmaceuticals: Is Trying To Copy What Works A Good Product Development Strategy?

via: SeekingAlpha at 2018-07-30 19:43:40:000

Ive been following Ra Pharmaceuticals ( RARX ) to some extent over the last few years due to my interest in rare diseases and the complement space. After discussing the company and its approach with one of our valued Growth Stock Forum members in the chat room, I decided to take a de… read more...

Ra Pharmaceuticals: Is Trying To Copy What Works A Good Product Development Strategy?

via: SeekingAlpha at 2018-07-30 19:43:40:000

Ive been following Ra Pharmaceuticals ( RARX ) to some extent over the last few years due to my interest in rare diseases and the complement space. After discussing the company and its approach with one of our valued Growth Stock Forum members in the chat room, I decided to take a de… read more...

Alexion Pharmaceuticals, Inc. 2018 Q2 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-07-26 13:56:11:000

The following slide deck was published by Alexion Pharmaceuticals, Inc. in conjunction with their 2018 Q2 earnings Read more … read more...

Alexion Pharmaceuticals, Inc. 2018 Q2 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-07-26 13:56:11:000

The following slide deck was published by Alexion Pharmaceuticals, Inc. in conjunction with their 2018 Q2 earnings Read more … read more...

Alexion Pharmaceuticals, Inc. 2018 Q2 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-07-26 13:56:11:000

The following slide deck was published by Alexion Pharmaceuticals, Inc. in conjunction with their 2018 Q2 earnings Read more … read more...

Alexion Pharmaceuticals, Inc. 2018 Q2 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-07-26 13:56:11:000

The following slide deck was published by Alexion Pharmaceuticals, Inc. in conjunction with their 2018 Q2 earnings Read more … read more...

Alexion Pharmaceuticals (ALXN) Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-07-26 12:05:09:000

Alexion Pharmaceuticals, Inc. (ALXN) Q2 2018 Earnings Call July 26, 2018 8:00 am ET Executives Susan Altschuller - Alexion Pharmaceuticals, Inc. Ludwig N. Hantson - Alexion Pharmaceuticals, Inc. Paul J. Clancy - Alexion Pharmaceuticals, Inc. John J. Orloff - Alexion Pharmaceuti… read more...

Alexion Pharmaceuticals (ALXN) Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-07-26 12:05:09:000

Alexion Pharmaceuticals, Inc. (ALXN) Q2 2018 Earnings Call July 26, 2018 8:00 am ET Executives Susan Altschuller - Alexion Pharmaceuticals, Inc. Ludwig N. Hantson - Alexion Pharmaceuticals, Inc. Paul J. Clancy - Alexion Pharmaceuticals, Inc. John J. Orloff - Alexion Pharmaceuti… read more...

Alexion Pharmaceuticals (ALXN) Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-07-26 12:05:09:000

Alexion Pharmaceuticals, Inc. (ALXN) Q2 2018 Earnings Call July 26, 2018 8:00 am ET Executives Susan Altschuller - Alexion Pharmaceuticals, Inc. Ludwig N. Hantson - Alexion Pharmaceuticals, Inc. Paul J. Clancy - Alexion Pharmaceuticals, Inc. John J. Orloff - Alexion Pharmaceuti… read more...

Alexion Pharmaceuticals (ALXN) Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-07-26 12:05:09:000

Alexion Pharmaceuticals, Inc. (ALXN) Q2 2018 Earnings Call July 26, 2018 8:00 am ET Executives Susan Altschuller - Alexion Pharmaceuticals, Inc. Ludwig N. Hantson - Alexion Pharmaceuticals, Inc. Paul J. Clancy - Alexion Pharmaceuticals, Inc. John J. Orloff - Alexion Pharmaceuti… read more...

Alexion Pharmaceuticals beats by $0.37, beats on revenue

via: SeekingAlpha at 2018-07-26 06:32:22:000

Alexion Pharmaceuticals (NASDAQ: ALXN ): Q2 EPS of $2.07 beats by $0.37 . More news on: Alexion Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Alexion Pharmaceuticals beats by $0.37, beats on revenue

via: SeekingAlpha at 2018-07-26 06:32:22:000

Alexion Pharmaceuticals (NASDAQ: ALXN ): Q2 EPS of $2.07 beats by $0.37 . More news on: Alexion Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Alexion Pharmaceuticals beats by $0.37, beats on revenue

via: SeekingAlpha at 2018-07-26 06:32:22:000

Alexion Pharmaceuticals (NASDAQ: ALXN ): Q2 EPS of $2.07 beats by $0.37 . More news on: Alexion Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Alexion Pharmaceuticals beats by $0.37, beats on revenue

via: SeekingAlpha at 2018-07-26 06:32:22:000

Alexion Pharmaceuticals (NASDAQ: ALXN ): Q2 EPS of $2.07 beats by $0.37 . More news on: Alexion Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Alexion Reports Second Quarter 2018 Results

via: Business Wire at 2018-07-26 06:30:00:000

2Q18 total revenues of $1,045.0 million, a 14 percent increase over 2Q17 and a 16 percent volume increase 2Q18 GAAP diluted EPS of $(2.05) per share; non-GAAP diluted EPS of $2.07 per share Filed ALXN1210 submissions for PNH approval in the U.S. and EU and on track to file in Japan… read more...

Alexion Reports Second Quarter 2018 Results

via: Business Wire at 2018-07-26 06:30:00:000

2Q18 total revenues of $1,045.0 million, a 14 percent increase over 2Q17 and a 16 percent volume increase 2Q18 GAAP diluted EPS of $(2.05) per share; non-GAAP diluted EPS of $2.07 per share Filed ALXN1210 submissions for PNH approval in the U.S. and EU and on track to file in Japan… read more...

Alexion Reports Second Quarter 2018 Results

via: Business Wire at 2018-07-26 06:30:00:000

2Q18 total revenues of $1,045.0 million, a 14 percent increase over 2Q17 and a 16 percent volume increase 2Q18 GAAP diluted EPS of $(2.05) per share; non-GAAP diluted EPS of $2.07 per share Filed ALXN1210 submissions for PNH approval in the U.S. and EU and on track to file in Japan… read more...

Alexion Reports Second Quarter 2018 Results

via: Business Wire at 2018-07-26 06:30:00:000

2Q18 total revenues of $1,045.0 million, a 14 percent increase over 2Q17 and a 16 percent volume increase 2Q18 GAAP diluted EPS of $(2.05) per share; non-GAAP diluted EPS of $2.07 per share Filed ALXN1210 submissions for PNH approval in the U.S. and EU and on track to file in Japan… read more...

Notable earnings before Thursday's open

via: SeekingAlpha at 2018-07-25 17:30:13:000

AAL , AAN , AB , ABMD , ADNT , AGN , AIMC , ALK , ALKS , ALLE , ALLY , ALXN , APD , ARD , ASPS , AUO , AXE , AXTA , AZN , BANC , BAX , BC , BMS , BMY , BUD , BWA , CELG , CFR , CMCSA , CME , CMS , CNHI , COLB , COP , COR , COWN , CPG , CRI , CRR , CTS… read more...

Riding Ra Pharmaceuticals

via: SeekingAlpha at 2018-07-23 06:12:13:000

Shares of Ra Pharmaceuticals (NASDAQ: RARX ) have so far been a classically successful insider-inspired investment idea, with the volatility of this high-risk/high-reward development-stage biotech definitely biased to the upside so far in our 5-month holding period. With an 86% gain in RARX,… read more...

Riding Ra Pharmaceuticals

via: SeekingAlpha at 2018-07-23 06:12:13:000

Shares of Ra Pharmaceuticals (NASDAQ: RARX ) have so far been a classically successful insider-inspired investment idea, with the volatility of this high-risk/high-reward development-stage biotech definitely biased to the upside so far in our 5-month holding period. With an 86% gain in RARX,… read more...

Arbutus Biopharma: Long-Term Growth Prospect Flying Too Close To The Sun

via: SeekingAlpha at 2018-07-18 16:03:11:000

While enthusiasm may be necessary for great accomplishments elsewhere, on Wall Street it almost invariably leads to disaster. -Benjamin Graham, The Intelligent Investor It's no wonder The Street has witnessed a 200% run-up over the past year for Arbutus Biopharma ( ABUS ). The Canadi… read more...

Arbutus Biopharma: Long-Term Growth Prospect Flying Too Close To The Sun

via: SeekingAlpha at 2018-07-18 16:03:11:000

While enthusiasm may be necessary for great accomplishments elsewhere, on Wall Street it almost invariably leads to disaster. -Benjamin Graham, The Intelligent Investor It's no wonder The Street has witnessed a 200% run-up over the past year for Arbutus Biopharma ( ABUS ). The Canadi… read more...

Arbutus Biopharma: Long-Term Growth Prospect Flying Too Close To The Sun

via: SeekingAlpha at 2018-07-18 16:03:11:000

While enthusiasm may be necessary for great accomplishments elsewhere, on Wall Street it almost invariably leads to disaster. -Benjamin Graham, The Intelligent Investor It's no wonder The Street has witnessed a 200% run-up over the past year for Arbutus Biopharma ( ABUS ). The Canadi… read more...

Alexion Pharmaceuticals' Diversification Strategy Makes It A Solid Buy For 2018

via: SeekingAlpha at 2018-07-18 10:17:28:000

Lately, many things seem to be working in favor of Alexion Pharmaceuticals ( ALXN ). We see Soliris continuing to perform exceptionally well, not only in Paroxysmal Nocturnal Hemoglobinuria or PNH and Atypical Hemolytic Uremic Syndrome or AHUS indications but also in the recently launched gene… read more...

Alexion Pharmaceuticals' Diversification Strategy Makes It A Solid Buy For 2018

via: SeekingAlpha at 2018-07-18 10:17:28:000

Lately, many things seem to be working in favor of Alexion Pharmaceuticals ( ALXN ). We see Soliris continuing to perform exceptionally well, not only in Paroxysmal Nocturnal Hemoglobinuria or PNH and Atypical Hemolytic Uremic Syndrome or AHUS indications but also in the recently launched gene… read more...

Alexion Pharmaceuticals' Diversification Strategy Makes It A Solid Buy For 2018

via: SeekingAlpha at 2018-07-18 10:17:28:000

Lately, many things seem to be working in favor of Alexion Pharmaceuticals ( ALXN ). We see Soliris continuing to perform exceptionally well, not only in Paroxysmal Nocturnal Hemoglobinuria or PNH and Atypical Hemolytic Uremic Syndrome or AHUS indications but also in the recently launched gene… read more...

Achillion Pharmaceuticals - Biotech Gold For The Price Of Dirt

via: SeekingAlpha at 2018-07-09 12:45:57:000

Welcome to Achillion ( ACHN ) - I've been following the company for a bit, but only after the JNJ Hep C disaster, so I won't be painting much of a picture for that asset, nor times before it. Rather I want to focus on lead asset 4471 and their second-generation drugs. And the ridiculous amount… read more...

Achillion Pharmaceuticals - Biotech Gold For The Price Of Dirt

via: SeekingAlpha at 2018-07-09 12:45:57:000

Welcome to Achillion ( ACHN ) - I've been following the company for a bit, but only after the JNJ Hep C disaster, so I won't be painting much of a picture for that asset, nor times before it. Rather I want to focus on lead asset 4471 and their second-generation drugs. And the ridiculous amount… read more...

Achillion Pharmaceuticals - Biotech Gold For The Price Of Dirt

via: SeekingAlpha at 2018-07-09 12:45:57:000

Welcome to Achillion ( ACHN ) - I've been following the company for a bit, but only after the JNJ Hep C disaster, so I won't be painting much of a picture for that asset, nor times before it. Rather I want to focus on lead asset 4471 and their second-generation drugs. And the ridiculous amount… read more...

3 Things In Biotech, June 30: Aptose Gets Rolling Again; Tesaro Heads To China; Alexion Goes Big Across The Pond

via: SeekingAlpha at 2018-06-30 08:00:00:000

Hello all, and welcome to another edition of 3 Things in Biotech. Today, I'm going to do something a little extra for you. I'm offering a sneak peek into what members of the Total Pharma Tracker get every day. If you like what you see and would like to get more ideas like this each day, cons… read more...

3 Things In Biotech, June 30: Aptose Gets Rolling Again; Tesaro Heads To China; Alexion Goes Big Across The Pond

via: SeekingAlpha at 2018-06-30 08:00:00:000

Hello all, and welcome to another edition of 3 Things in Biotech. Today, I'm going to do something a little extra for you. I'm offering a sneak peek into what members of the Total Pharma Tracker get every day. If you like what you see and would like to get more ideas like this each day, cons… read more...

3 Things In Biotech, June 30: Aptose Gets Rolling Again; Tesaro Heads To China; Alexion Goes Big Across The Pond

via: SeekingAlpha at 2018-06-30 08:00:00:000

Hello all, and welcome to another edition of 3 Things in Biotech. Today, I'm going to do something a little extra for you. I'm offering a sneak peek into what members of the Total Pharma Tracker get every day. If you like what you see and would like to get more ideas like this each day, cons… read more...

3 Things In Biotech, June 30: Aptose Gets Rolling Again; Tesaro Heads To China; Alexion Goes Big Across The Pond

via: SeekingAlpha at 2018-06-30 08:00:00:000

Hello all, and welcome to another edition of 3 Things in Biotech. Today, I'm going to do something a little extra for you. I'm offering a sneak peek into what members of the Total Pharma Tracker get every day. If you like what you see and would like to get more ideas like this each day, cons… read more...

Alexion to Report Second Quarter 2018 Results on Thursday, July 26, 2018

via: Business Wire at 2018-06-28 16:30:00:000

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the second quarter ended June 30, 2018 before the US financial markets open on July 26, 2018. Following the release of the financial results, Alexion management will conduct a … read more...

Alexion to Report Second Quarter 2018 Results on Thursday, July 26, 2018

via: Business Wire at 2018-06-28 16:30:00:000

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the second quarter ended June 30, 2018 before the US financial markets open on July 26, 2018. Following the release of the financial results, Alexion management will conduct a … read more...

Alexion Submits Application for Approval of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) in the European Union (EU)

via: Business Wire at 2018-06-28 06:30:00:000

-- EU Filing Follows U.S. Filing in June 2018 -- -- Submission in Japan on Track for the Second Half of the Year -- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the submission of a Marketing Authorization Application to the European Medicines Agency (EMA) for ALXN1… read more...

Alexion Submits Application for Approval of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) in the European Union (EU)

via: Business Wire at 2018-06-28 06:30:00:000

-- EU Filing Follows U.S. Filing in June 2018 -- -- Submission in Japan on Track for the Second Half of the Year -- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the submission of a Marketing Authorization Application to the European Medicines Agency (EMA) for ALXN1… read more...

Your Daily Pharma Scoop: Anika Fails Trial, Kala's Upcoming Catalyst, Sarepta Surges

via: SeekingAlpha at 2018-06-21 08:00:00:000

Analysis Focus: ANIK Anika Therapeutics ( ANIK ) announced failure of its candidate CINGAL to achieve primary endpoint in a Phase 3 clinical trial in knee osteoarthritis (OA). CINGAL could not succeed in showing a statistically significant reduction in knee pain. CINGAL is a combin… read more...

Your Daily Pharma Scoop: Anika Fails Trial, Kala's Upcoming Catalyst, Sarepta Surges

via: SeekingAlpha at 2018-06-21 08:00:00:000

Analysis Focus: ANIK Anika Therapeutics ( ANIK ) announced failure of its candidate CINGAL to achieve primary endpoint in a Phase 3 clinical trial in knee osteoarthritis (OA). CINGAL could not succeed in showing a statistically significant reduction in knee pain. CINGAL is a combin… read more...

Alexion files U.S. marketing application for ALXN1210 for PNH

via: SeekingAlpha at 2018-06-19 07:00:04:000

Alexion Pharmaceuticals (NASDAQ: ALXN ) submits a marketing application to the FDA seeking approval for Orphan Drug-tagged ALXN1210 for the treatment paroxysmal nocturnal hemoglobinuria (PNH). More news on: Alexion Pharmaceuticals, Inc., Healthcare stocks news, Read more … read more...

Alexion files U.S. marketing application for ALXN1210 for PNH

via: SeekingAlpha at 2018-06-19 07:00:04:000

Alexion Pharmaceuticals (NASDAQ: ALXN ) submits a marketing application to the FDA seeking approval for Orphan Drug-tagged ALXN1210 for the treatment paroxysmal nocturnal hemoglobinuria (PNH). More news on: Alexion Pharmaceuticals, Inc., Healthcare stocks news, Read more … read more...

Alexion Submits Application for Priority Review and Approval of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) in the U.S.

via: Business Wire at 2018-06-19 06:30:00:000

-- Use of Priority Review Voucher Provides Expedited Review of Eight Months -- -- Submission in the European Union on Track for Mid-Year and in Japan for the Second Half of the Year -- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the submission of a Biologics Licen… read more...

Alexion Submits Application for Priority Review and Approval of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) in the U.S.

via: Business Wire at 2018-06-19 06:30:00:000

-- Use of Priority Review Voucher Provides Expedited Review of Eight Months -- -- Submission in the European Union on Track for Mid-Year and in Japan for the Second Half of the Year -- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the submission of a Biologics Licen… read more...

A Review Of Adeno-Associated Virus Mediated Gene Therapies And A Closer Look At Adverum's ADV-043

via: SeekingAlpha at 2018-06-18 08:15:00:000

Gene Therapy In Context Few terms in medicine invoke more awe and fascination than Gene Therapy. Ever since the discovery of DNA and our understanding that within the basic genetic code lies the basis for so many different disease states, scientists have plotted to devise ways to f… read more...

Alexion Announces Selection of Positive Phase 3 Clinical Data for ALXN1210 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) for Late-Breaking Oral Presentation at Annual Conference of the European Hematology Association (EHA)

via: Business Wire at 2018-06-14 07:30:00:000

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that positive results from one of the two large Phase 3 studies of ALXN1210, the Companys investigational long-acting C5 complement inhibitor, in patients with paroxysmal nocturnal hemoglobinuria (PNH) were selected for pres… read more...

Alexion Announces Selection of Positive Phase 3 Clinical Data for ALXN1210 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) for Late-Breaking Oral Presentation at Annual Conference of the European Hematology Association (EHA)

via: Business Wire at 2018-06-14 07:30:00:000

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that positive results from one of the two large Phase 3 studies of ALXN1210, the Companys investigational long-acting C5 complement inhibitor, in patients with paroxysmal nocturnal hemoglobinuria (PNH) were selected for pres… read more...

Alexion Announces Selection of Positive Phase 3 Clinical Data for ALXN1210 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) for Late-Breaking Oral Presentation at Annual Conference of the European Hematology Association (EHA)

via: Business Wire at 2018-06-14 07:30:00:000

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that positive results from one of the two large Phase 3 studies of ALXN1210, the Companys investigational long-acting C5 complement inhibitor, in patients with paroxysmal nocturnal hemoglobinuria (PNH) were selected for pres… read more...

Alexion and Complement Pharma Announce Partnership to Co-Develop Pre-Clinical Complement Inhibitor for Neurodegenerative Disorders

via: Business Wire at 2018-06-11 07:30:00:000

Collaboration provides opportunity to expand on Alexions two decades of complement leadership Complement Pharma to receive up to a total of 14 million in milestone-dependent payments through Phase 1b development Alexion has option to acquire Complement Pharma durin… read more...

Alexion and Complement Pharma Announce Partnership to Co-Develop Pre-Clinical Complement Inhibitor for Neurodegenerative Disorders

via: Business Wire at 2018-06-11 07:30:00:000

Collaboration provides opportunity to expand on Alexions two decades of complement leadership Complement Pharma to receive up to a total of 14 million in milestone-dependent payments through Phase 1b development Alexion has option to acquire Complement Pharma durin… read more...

Alexion and Complement Pharma Announce Partnership to Co-Develop Pre-Clinical Complement Inhibitor for Neurodegenerative Disorders

via: Business Wire at 2018-06-11 07:30:00:000

Collaboration provides opportunity to expand on Alexions two decades of complement leadership Complement Pharma to receive up to a total of 14 million in milestone-dependent payments through Phase 1b development Alexion has option to acquire Complement Pharma durin… read more...

Core Biotech Buys #18: Thoughts On ASCO And The End Of Core Biotech

via: SeekingAlpha at 2018-06-07 16:03:56:000

Welcome to the eighteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size… read more...

Core Biotech Buys #18: Thoughts On ASCO And The End Of Core Biotech

via: SeekingAlpha at 2018-06-07 16:03:56:000

Welcome to the eighteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size… read more...

Core Biotech Buys #18: Thoughts On ASCO And The End Of Core Biotech

via: SeekingAlpha at 2018-06-07 16:03:56:000

Welcome to the eighteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size… read more...

Alexion to Present at the Goldman Sachs 39th Annual Global Healthcare Conference

via: Business Wire at 2018-06-05 16:30:00:000

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at the Goldman Sachs 39th Annual Global Healthcare Conference in Rancho Palos Verdes, CA on Tuesday, June 12, 2018 at 11:20 a.m., PDT. An audio webcast of the presentation will be available live. You can … read more...

Alexion to Present at the Goldman Sachs 39th Annual Global Healthcare Conference

via: Business Wire at 2018-06-05 16:30:00:000

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at the Goldman Sachs 39th Annual Global Healthcare Conference in Rancho Palos Verdes, CA on Tuesday, June 12, 2018 at 11:20 a.m., PDT. An audio webcast of the presentation will be available live. You can … read more...

Omeros Corporation: OMS721 In HSCT-TMA And IgAN Plus Omidria Worth $2.5 Billion

via: SeekingAlpha at 2018-06-05 10:00:00:000

Introduction Dr. George Crist and I co-manage an investment fund together and we believe, based on the events which have recently transpired, as well as the expected catalysts we see coming in the immediate future, that Omeros Corporation (OMER) is substantially undervalued and presents an… read more...

Omeros Corporation: OMS721 In HSCT-TMA And IgAN Plus Omidria Worth $2.5 Billion

via: SeekingAlpha at 2018-06-05 10:00:00:000

Introduction Dr. George Crist and I co-manage an investment fund together and we believe, based on the events which have recently transpired, as well as the expected catalysts we see coming in the immediate future, that Omeros Corporation (OMER) is substantially undervalued and presents an… read more...

Institutional Top Ideas Series: Biotechnology Value Fund

via: SeekingAlpha at 2018-06-04 09:19:47:000

In the last entry of this series, we took a look at top ideas from Perceptive Advisors, a hedge fund with a highly enviable track record characterized by impressive consistency and high returns. Going forward, I hope to continue to delve into the portfolios of successful hedge funds predo… read more...

Core Biotech Buys #17: Positive Commentary For Gene Therapy And Our First Swap

via: SeekingAlpha at 2018-05-31 13:23:00:000

Welcome to the seventeenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the siz… read more...

Core Biotech Buys #17: Positive Commentary For Gene Therapy And Our First Swap

via: SeekingAlpha at 2018-05-31 13:23:00:000

Welcome to the seventeenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the siz… read more...

Core Biotech Buys #17: Positive Commentary For Gene Therapy And Our First Swap

via: SeekingAlpha at 2018-05-31 13:23:00:000

Welcome to the seventeenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the siz… read more...

Alexion Pharmaceuticals: Clinical Progress, Acquisitions And The Competition (Part 2)

via: SeekingAlpha at 2018-05-31 09:04:00:000

This article is the second of two parts discussing Alexion Pharmaceuticals ( ALXN ) and its competition. Make sure to check out Part 1 here if you have not already. In Part 2 I will focus mostly on ALXNs competition. I have previously reviewed a large number of ALXNs compet… read more...

Alexion Pharmaceuticals: Clinical Progress, Acquisitions And The Competition (Part 2)

via: SeekingAlpha at 2018-05-31 09:04:00:000

This article is the second of two parts discussing Alexion Pharmaceuticals ( ALXN ) and its competition. Make sure to check out Part 1 here if you have not already. In Part 2 I will focus mostly on ALXNs competition. I have previously reviewed a large number of ALXNs compet… read more...

Alexion Pharmaceuticals: Clinical Progress, Acquisitions And The Competition (Part 2)

via: SeekingAlpha at 2018-05-31 09:04:00:000

This article is the second of two parts discussing Alexion Pharmaceuticals ( ALXN ) and its competition. Make sure to check out Part 1 here if you have not already. In Part 2 I will focus mostly on ALXNs competition. I have previously reviewed a large number of ALXNs compet… read more...

Your Daily Pharma Scoop: Recent IPO And Offerings Review

via: SeekingAlpha at 2018-05-31 04:02:59:000

IPO As a general rule, we dont invest in IPOs. It is too risky. What is an IPO but an unknown/unproven business asking for your money to chase some dream of theirs. But many people like dreams, so when an IPO gets launched - assuming theres enough hype - the stock soars f… read more...

Your Daily Pharma Scoop: Recent IPO And Offerings Review

via: SeekingAlpha at 2018-05-31 04:02:59:000

IPO As a general rule, we dont invest in IPOs. It is too risky. What is an IPO but an unknown/unproven business asking for your money to chase some dream of theirs. But many people like dreams, so when an IPO gets launched - assuming theres enough hype - the stock soars f… read more...

Your Daily Pharma Scoop: Recent IPO And Offerings Review

via: SeekingAlpha at 2018-05-31 04:02:59:000

IPO As a general rule, we dont invest in IPOs. It is too risky. What is an IPO but an unknown/unproven business asking for your money to chase some dream of theirs. But many people like dreams, so when an IPO gets launched - assuming theres enough hype - the stock soars f… read more...

Alexion offer for Wilson Therapeutics accepted

via: SeekingAlpha at 2018-05-25 08:01:53:000

Alexion Pharmaceuticals' (NASDAQ: ALXN ) offer through a wholly owned subsidiary, for the shares in Wilson Therapeutics has been accepted by shareholders representing 97.7% of the total number of shares and votes. More news on: Alexion Pharmaceuticals, Inc., Healthcare stocks news, R… read more...

Alexion offer for Wilson Therapeutics accepted

via: SeekingAlpha at 2018-05-25 08:01:53:000

Alexion Pharmaceuticals' (NASDAQ: ALXN ) offer through a wholly owned subsidiary, for the shares in Wilson Therapeutics has been accepted by shareholders representing 97.7% of the total number of shares and votes. More news on: Alexion Pharmaceuticals, Inc., Healthcare stocks news, R… read more...

Alexion offer for Wilson Therapeutics accepted

via: SeekingAlpha at 2018-05-25 08:01:53:000

Alexion Pharmaceuticals' (NASDAQ: ALXN ) offer through a wholly owned subsidiary, for the shares in Wilson Therapeutics has been accepted by shareholders representing 97.7% of the total number of shares and votes. More news on: Alexion Pharmaceuticals, Inc., Healthcare stocks news, R… read more...

Alexion offer for Wilson Therapeutics accepted

via: SeekingAlpha at 2018-05-25 08:01:53:000

Alexion Pharmaceuticals' (NASDAQ: ALXN ) offer through a wholly owned subsidiary, for the shares in Wilson Therapeutics has been accepted by shareholders representing 97.7% of the total number of shares and votes. More news on: Alexion Pharmaceuticals, Inc., Healthcare stocks news, R… read more...

Alexion offer for Wilson Therapeutics accepted

via: SeekingAlpha at 2018-05-25 08:01:53:000

Alexion Pharmaceuticals' (NASDAQ: ALXN ) offer through a wholly owned subsidiary, for the shares in Wilson Therapeutics has been accepted by shareholders representing 97.7% of the total number of shares and votes. More news on: Alexion Pharmaceuticals, Inc., Healthcare stocks news, R… read more...

Alexion offer for Wilson Therapeutics accepted

via: SeekingAlpha at 2018-05-25 08:01:53:000

Alexion Pharmaceuticals' (NASDAQ: ALXN ) offer through a wholly owned subsidiary, for the shares in Wilson Therapeutics has been accepted by shareholders representing 97.7% of the total number of shares and votes. More news on: Alexion Pharmaceuticals, Inc., Healthcare stocks news, R… read more...

Alexion Offer for Wilson Therapeutics Accepted

via: Business Wire at 2018-05-25 01:05:00:000

Offer accepted by shareholders representing 97.7% of shares and votes in Wilson Therapeutics Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that its offer, through a wholly owned subsidiary, for the shares in Wilson Therapeutics has been accepted by sh… read more...

Alexion Offer for Wilson Therapeutics Accepted

via: Business Wire at 2018-05-25 01:05:00:000

Offer accepted by shareholders representing 97.7% of shares and votes in Wilson Therapeutics Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that its offer, through a wholly owned subsidiary, for the shares in Wilson Therapeutics has been accepted by sh… read more...

Alexion Offer for Wilson Therapeutics Accepted

via: Business Wire at 2018-05-25 01:05:00:000

Offer accepted by shareholders representing 97.7% of shares and votes in Wilson Therapeutics Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that its offer, through a wholly owned subsidiary, for the shares in Wilson Therapeutics has been accepted by sh… read more...

Alexion Offer for Wilson Therapeutics Accepted

via: Business Wire at 2018-05-25 01:05:00:000

Offer accepted by shareholders representing 97.7% of shares and votes in Wilson Therapeutics Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that its offer, through a wholly owned subsidiary, for the shares in Wilson Therapeutics has been accepted by sh… read more...

Alexion Offer for Wilson Therapeutics Accepted

via: Business Wire at 2018-05-25 01:05:00:000

Offer accepted by shareholders representing 97.7% of shares and votes in Wilson Therapeutics Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that its offer, through a wholly owned subsidiary, for the shares in Wilson Therapeutics has been accepted by sh… read more...

Alexion Offer for Wilson Therapeutics Accepted

via: Business Wire at 2018-05-25 01:05:00:000

Offer accepted by shareholders representing 97.7% of shares and votes in Wilson Therapeutics Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that its offer, through a wholly owned subsidiary, for the shares in Wilson Therapeutics has been accepted by sh… read more...

Alexion Pharmaceuticals: Clinical Progress, Acquisitions And The Competition (Part 1)

via: SeekingAlpha at 2018-05-25 00:21:59:000

Alexion Pharmaceuticals ( ALXN ) is a biopharmaceutical company which markets Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). Most of ALXNs revenues come from Soliris, an antibody which binds the complement protein C5, which is currently approved to treat t… read more...

Alexion Pharmaceuticals: Clinical Progress, Acquisitions And The Competition (Part 1)

via: SeekingAlpha at 2018-05-25 00:21:59:000

Alexion Pharmaceuticals ( ALXN ) is a biopharmaceutical company which markets Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). Most of ALXNs revenues come from Soliris, an antibody which binds the complement protein C5, which is currently approved to treat t… read more...

Alexion Pharmaceuticals: Clinical Progress, Acquisitions And The Competition (Part 1)

via: SeekingAlpha at 2018-05-25 00:21:59:000

Alexion Pharmaceuticals ( ALXN ) is a biopharmaceutical company which markets Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). Most of ALXNs revenues come from Soliris, an antibody which binds the complement protein C5, which is currently approved to treat t… read more...

Alexion Pharmaceuticals: Clinical Progress, Acquisitions And The Competition (Part 1)

via: SeekingAlpha at 2018-05-25 00:21:59:000

Alexion Pharmaceuticals ( ALXN ) is a biopharmaceutical company which markets Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). Most of ALXNs revenues come from Soliris, an antibody which binds the complement protein C5, which is currently approved to treat t… read more...

Alexion Pharmaceuticals: Clinical Progress, Acquisitions And The Competition (Part 1)

via: SeekingAlpha at 2018-05-25 00:21:59:000

Alexion Pharmaceuticals ( ALXN ) is a biopharmaceutical company which markets Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). Most of ALXNs revenues come from Soliris, an antibody which binds the complement protein C5, which is currently approved to treat t… read more...

Alexion Pharmaceuticals: Clinical Progress, Acquisitions And The Competition (Part 1)

via: SeekingAlpha at 2018-05-25 00:21:59:000

Alexion Pharmaceuticals ( ALXN ) is a biopharmaceutical company which markets Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). Most of ALXNs revenues come from Soliris, an antibody which binds the complement protein C5, which is currently approved to treat t… read more...

Institutional Top Ideas Series: Perceptive Advisors

via: SeekingAlpha at 2018-05-24 01:54:56:000

In the last entry of this series, we took a look at top ideas from Opaleye Management, one of the best performing funds we've come across so far thats been growing its AUM at an impressive rate. Going forward, I hope to continue to delve into the portfolios of successful hedge funds … read more...

Institutional Top Ideas Series: Perceptive Advisors

via: SeekingAlpha at 2018-05-24 01:54:56:000

In the last entry of this series, we took a look at top ideas from Opaleye Management, one of the best performing funds we've come across so far thats been growing its AUM at an impressive rate. Going forward, I hope to continue to delve into the portfolios of successful hedge funds … read more...

Institutional Top Ideas Series: Perceptive Advisors

via: SeekingAlpha at 2018-05-24 01:54:56:000

In the last entry of this series, we took a look at top ideas from Opaleye Management, one of the best performing funds we've come across so far thats been growing its AUM at an impressive rate. Going forward, I hope to continue to delve into the portfolios of successful hedge funds … read more...

Institutional Top Ideas Series: Perceptive Advisors

via: SeekingAlpha at 2018-05-24 01:54:56:000

In the last entry of this series, we took a look at top ideas from Opaleye Management, one of the best performing funds we've come across so far thats been growing its AUM at an impressive rate. Going forward, I hope to continue to delve into the portfolios of successful hedge funds … read more...

Core Biotech Buys #16: Taking Advantage Of Weakness To Add To Conviction Ideas

via: SeekingAlpha at 2018-05-22 12:03:38:000

Welcome to the sixteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size … read more...

JF's Core Biotech Buys #15: Removal Of A Key Overhang, Buying Weakness In I-O, Updates And Adding To 2 Positions

via: SeekingAlpha at 2018-05-14 11:37:23:000

Welcome to the fifteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size … read more...

JF's Core Biotech Buys #15: Removal Of A Key Overhang, Buying Weakness In I-O, Updates And Adding To 2 Positions

via: SeekingAlpha at 2018-05-14 11:37:23:000

Welcome to the fifteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size … read more...

Institutional Top Ideas Series: Ra Capital Management

via: SeekingAlpha at 2018-05-10 02:04:51:000

In the last entry of this series we took a look at top ideas from Orbimed Advisors, a large fund in the midst of a leadership transition which avoids outsized bets (over 5% weighting) yet still has posted decent returns. Going forward, I hope to continue to delve into the portfolios of su… read more...

Institutional Top Ideas Series: Ra Capital Management

via: SeekingAlpha at 2018-05-10 02:04:51:000

In the last entry of this series we took a look at top ideas from Orbimed Advisors, a large fund in the midst of a leadership transition which avoids outsized bets (over 5% weighting) yet still has posted decent returns. Going forward, I hope to continue to delve into the portfolios of su… read more...

Alexion to Present at the Bank of America Merrill Lynch 2018 Health Care Conference

via: Business Wire at 2018-05-08 16:30:00:000

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at the Bank of America Merrill Lynch Health Care Conference in Las Vegas on Wednesday, May 16, 2018 at 2:20 p.m., PDT. An audio webcast of the presentation will be available live. You can access the webca… read more...

Alexion to Present at the Bank of America Merrill Lynch 2018 Health Care Conference

via: Business Wire at 2018-05-08 16:30:00:000

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at the Bank of America Merrill Lynch Health Care Conference in Las Vegas on Wednesday, May 16, 2018 at 2:20 p.m., PDT. An audio webcast of the presentation will be available live. You can access the webca… read more...

JF's Core Biotech Buys #14: Introducing Our Final 2 Positions & Taking Advantage Of Weakness In The I-O Space

via: SeekingAlpha at 2018-05-07 15:40:31:000

Welcome to the fourteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size… read more...

JF's Core Biotech Buys #14: Introducing Our Final 2 Positions & Taking Advantage Of Weakness In The I-O Space

via: SeekingAlpha at 2018-05-07 15:40:31:000

Welcome to the fourteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size… read more...

Daily Insider Ratings Round Up 5/2/18: SOHU, BW, DDR, NHF, ABCP, ALXN

via: SeekingAlpha at 2018-05-05 14:36:43:000

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...

Daily Insider Ratings Round Up 5/2/18: SOHU, BW, DDR, NHF, ABCP, ALXN

via: SeekingAlpha at 2018-05-05 14:36:43:000

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...

Institutional Top Ideas Series: Orbimed Advisors

via: SeekingAlpha at 2018-05-04 03:18:51:000

In the last entry of this series, we took a look at top ideas from Baker Bros. Advisors (whose performance has been struggling of late but they've built up a stellar reputation and track record of long term outperformance). Going forward, I hope to continue to delve into the portfolios of… read more...

Institutional Top Ideas Series: Orbimed Advisors

via: SeekingAlpha at 2018-05-04 03:18:51:000

In the last entry of this series, we took a look at top ideas from Baker Bros. Advisors (whose performance has been struggling of late but they've built up a stellar reputation and track record of long term outperformance). Going forward, I hope to continue to delve into the portfolios of… read more...

How To Play 'Am I Diversified?' In The Pharma/Biotech Space

via: SeekingAlpha at 2018-05-03 00:54:16:000

Background Many investors (including myself) regularly watch or listen to the show "Mad Money" by Jim Cramer on CNBC. As with any celebrity, Mr. Cramer tends to be polarizing, with some loving him and some reveling in pointing out when he is wrong. Rather than focusing on his individual stoc… read more...

How To Play 'Am I Diversified?' In The Pharma/Biotech Space

via: SeekingAlpha at 2018-05-03 00:54:16:000

Background Many investors (including myself) regularly watch or listen to the show "Mad Money" by Jim Cramer on CNBC. As with any celebrity, Mr. Cramer tends to be polarizing, with some loving him and some reveling in pointing out when he is wrong. Rather than focusing on his individual stoc… read more...

JF's Core Biotech Buys #13: Continued Market Headwinds And How To Respond

via: SeekingAlpha at 2018-05-01 02:41:27:000

Welcome to the thirteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size… read more...

JF's Core Biotech Buys #13: Continued Market Headwinds And How To Respond

via: SeekingAlpha at 2018-05-01 02:41:27:000

Welcome to the thirteenth edition in the series "JF's Core Biotech Buys." Our model account utilizes a full position size of $5,000 and will hold up to 20 stocks. Trades will be less frequent with cost averages calculated at the day's close when an article is published. Depending on the size… read more...

Alexion Clears A Path For 2nd Generation PNH Drug

via: SeekingAlpha at 2018-04-30 04:36:41:000

Recently, Alexion Pharmaceuticals ( ALXN ) announced positive results from another phase 3 study for its second generation version of Soliris, known as ALXN1210. This study is good news for the company, because the trial showed that patients can be switched from soliris to ALXN1210 witho… read more...

3 Things In Biotech, April 27: AbbVie And Alexion Move Forward, ADC Moves Back

via: SeekingAlpha at 2018-04-28 08:01:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech You Should Learn Today," a… read more...

Alexion up 5% on difficulty in certain PNH patients switching from Soliris to Ra Pharma's RA101495

via: SeekingAlpha at 2018-02-12 12:55:18:000

A Phase 2 clinical trial assessing Ra Pharmaceuticals' ( RARX +2.4% ) subcutaneously administered RA101495 in patients with paroxysmal nocturnal hemoglobinuria (PNH) showed a positive effect in patients who were naive to Alexion Therapeutics' ( ALXN +5.3% ) Soliris (eculizumab). The da… read more...

Alexion up 5% on difficulty in certain PNH patients switching from Soliris to Ra Pharma's RA101495

via: SeekingAlpha at 2018-02-12 12:55:18:000

A Phase 2 clinical trial assessing Ra Pharmaceuticals' ( RARX +2.4% ) subcutaneously administered RA101495 in patients with paroxysmal nocturnal hemoglobinuria (PNH) showed a positive effect in patients who were naive to Alexion Therapeutics' ( ALXN +5.3% ) Soliris (eculizumab). The da… read more...

Biotech Forum Daily Digest For February 12th

via: SeekingAlpha at 2018-02-12 10:14:39:000

T here are some days we can claim and there are other days that claim us . Kamand Kojouri Investors got treated like 'rented mules' this week as the markets suffered their worst weekly loss in some two years. Four of the five trading sessions featured over 1,000 point sw… read more...

Biotech Forum Daily Digest For February 12th

via: SeekingAlpha at 2018-02-12 10:14:39:000

T here are some days we can claim and there are other days that claim us . Kamand Kojouri Investors got treated like 'rented mules' this week as the markets suffered their worst weekly loss in some two years. Four of the five trading sessions featured over 1,000 point sw… read more...

Alexion Pharmaceuticals - Appeal Increases, Not Pulling The Trigger Yet

via: SeekingAlpha at 2018-02-11 10:47:06:000

Alexion Pharmaceuticals ( ALXN ) is a great growth story within the biotechnology industry, having delivered on great returns for investors. The success of Alexion is driven by Soliris, after which the company has added two other products to its portfolio. Despite the fact that the company… read more...

Alexion Pharmaceuticals - Appeal Increases, Not Pulling The Trigger Yet

via: SeekingAlpha at 2018-02-11 10:47:06:000

Alexion Pharmaceuticals ( ALXN ) is a great growth story within the biotechnology industry, having delivered on great returns for investors. The success of Alexion is driven by Soliris, after which the company has added two other products to its portfolio. Despite the fact that the company… read more...

Alexion Pharmaceuticals - Appeal Increases, Not Pulling The Trigger Yet

via: SeekingAlpha at 2018-02-11 10:47:06:000

Alexion Pharmaceuticals ( ALXN ) is a great growth story within the biotechnology industry, having delivered on great returns for investors. The success of Alexion is driven by Soliris, after which the company has added two other products to its portfolio. Despite the fact that the company… read more...

Your Daily Pharma Scoop: Adamas' Gocovri Key Value Driver, BioMarin Data, Regeneron Q4 Results

via: SeekingAlpha at 2018-02-09 08:00:00:000

Analysis of top Seeking Alpha coverage: Adamas Pharmaceuticals Today we will focus on Adamas Pharmaceuticals ( ADMS ). On Thursday, the company reported data from the EASE LID 2 study. Adamas got an approval for Gocovri last year, the first treatment for levodopa induced dyskinesia i… read more...

Your Daily Pharma Scoop: Adamas' Gocovri Key Value Driver, BioMarin Data, Regeneron Q4 Results

via: SeekingAlpha at 2018-02-09 08:00:00:000

Analysis of top Seeking Alpha coverage: Adamas Pharmaceuticals Today we will focus on Adamas Pharmaceuticals ( ADMS ). On Thursday, the company reported data from the EASE LID 2 study. Adamas got an approval for Gocovri last year, the first treatment for levodopa induced dyskinesia i… read more...

Your Daily Pharma Scoop: Adamas' Gocovri Key Value Driver, BioMarin Data, Regeneron Q4 Results

via: SeekingAlpha at 2018-02-09 08:00:00:000

Analysis of top Seeking Alpha coverage: Adamas Pharmaceuticals Today we will focus on Adamas Pharmaceuticals ( ADMS ). On Thursday, the company reported data from the EASE LID 2 study. Adamas got an approval for Gocovri last year, the first treatment for levodopa induced dyskinesia i… read more...

Your Daily Pharma Scoop: Adamas' Gocovri Key Value Driver, BioMarin Data, Regeneron Q4 Results

via: SeekingAlpha at 2018-02-09 08:00:00:000

Analysis of top Seeking Alpha coverage: Adamas Pharmaceuticals Today we will focus on Adamas Pharmaceuticals ( ADMS ). On Thursday, the company reported data from the EASE LID 2 study. Adamas got an approval for Gocovri last year, the first treatment for levodopa induced dyskinesia i… read more...

Your Daily Pharma Scoop: Adamas' Gocovri Key Value Driver, BioMarin Data, Regeneron Q4 Results

via: SeekingAlpha at 2018-02-09 08:00:00:000

Analysis of top Seeking Alpha coverage: Adamas Pharmaceuticals Today we will focus on Adamas Pharmaceuticals ( ADMS ). On Thursday, the company reported data from the EASE LID 2 study. Adamas got an approval for Gocovri last year, the first treatment for levodopa induced dyskinesia i… read more...

Alexion Pharmaceuticals (ALXN) Q4 2017 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-02-08 15:25:08:000

Alexion Pharmaceuticals, Inc. (ALXN) Q4 2017 Earnings Call February 08, 2018 10:00 am ET Executives Elena H. Ridloff - Alexion Pharmaceuticals, Inc. Ludwig N. Hantson - Alexion Pharmaceuticals, Inc. Paul J. Clancy - Alexion Pharmaceuticals, Inc. Brian Goff - Alexion Pharmaceuti… read more...

Alexion Pharmaceuticals (ALXN) Q4 2017 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-02-08 15:25:08:000

Alexion Pharmaceuticals, Inc. (ALXN) Q4 2017 Earnings Call February 08, 2018 10:00 am ET Executives Elena H. Ridloff - Alexion Pharmaceuticals, Inc. Ludwig N. Hantson - Alexion Pharmaceuticals, Inc. Paul J. Clancy - Alexion Pharmaceuticals, Inc. Brian Goff - Alexion Pharmaceuti… read more...

Alexion Pharmaceuticals (ALXN) Q4 2017 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-02-08 15:25:08:000

Alexion Pharmaceuticals, Inc. (ALXN) Q4 2017 Earnings Call February 08, 2018 10:00 am ET Executives Elena H. Ridloff - Alexion Pharmaceuticals, Inc. Ludwig N. Hantson - Alexion Pharmaceuticals, Inc. Paul J. Clancy - Alexion Pharmaceuticals, Inc. Brian Goff - Alexion Pharmaceuti… read more...

Alexion Pharmaceuticals, Inc. 2017 Q4 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-02-08 09:20:10:000

The following slide deck was published by Alexion Pharmaceuticals, Inc. in conjunction with their 2017 Q4 earnings Read more … read more...

Alexion Pharmaceuticals, Inc. 2017 Q4 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-02-08 09:20:10:000

The following slide deck was published by Alexion Pharmaceuticals, Inc. in conjunction with their 2017 Q4 earnings Read more … read more...

Alexion Pharmaceuticals, Inc. 2017 Q4 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-02-08 09:20:10:000

The following slide deck was published by Alexion Pharmaceuticals, Inc. in conjunction with their 2017 Q4 earnings Read more … read more...

Alexion Pharmaceuticals, Inc. 2017 Q4 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-02-08 09:20:10:000

The following slide deck was published by Alexion Pharmaceuticals, Inc. in conjunction with their 2017 Q4 earnings Read more … read more...

Alexion Pharma Q4 revenues up 10%; non-GAAP EPS up 18%; updates guidance

via: SeekingAlpha at 2018-02-08 08:00:25:000

Alexion Pharmaceuticals ( ALXN +1.9% ) Q4 results : Revenues: $909.7M (+9.5%); Operating Income: $108.6M (-14.8%); Net Income: $30M (-67.7%); EPS: $0.13 (-68.3%); Non-GAAP EPS: $1.48 (+17.5%); Quick Assets: $1,474.1M (+14.0%). More news on: Alexion Pharmaceuticals, Inc., Healthcare stoc… read more...

Alexion Pharma Q4 revenues up 10%; non-GAAP EPS up 18%; updates guidance

via: SeekingAlpha at 2018-02-08 08:00:25:000

Alexion Pharmaceuticals ( ALXN +1.9% ) Q4 results : Revenues: $909.7M (+9.5%); Operating Income: $108.6M (-14.8%); Net Income: $30M (-67.7%); EPS: $0.13 (-68.3%); Non-GAAP EPS: $1.48 (+17.5%); Quick Assets: $1,474.1M (+14.0%). More news on: Alexion Pharmaceuticals, Inc., Healthcare stoc… read more...

Alexion Pharma Q4 revenues up 10%; non-GAAP EPS up 18%; updates guidance

via: SeekingAlpha at 2018-02-08 08:00:25:000

Alexion Pharmaceuticals ( ALXN +1.9% ) Q4 results : Revenues: $909.7M (+9.5%); Operating Income: $108.6M (-14.8%); Net Income: $30M (-67.7%); EPS: $0.13 (-68.3%); Non-GAAP EPS: $1.48 (+17.5%); Quick Assets: $1,474.1M (+14.0%). More news on: Alexion Pharmaceuticals, Inc., Healthcare stoc… read more...

Alexion Pharma Q4 revenues up 10%; non-GAAP EPS up 18%; updates guidance

via: SeekingAlpha at 2018-02-08 08:00:25:000

Alexion Pharmaceuticals ( ALXN +1.9% ) Q4 results : Revenues: $909.7M (+9.5%); Operating Income: $108.6M (-14.8%); Net Income: $30M (-67.7%); EPS: $0.13 (-68.3%); Non-GAAP EPS: $1.48 (+17.5%); Quick Assets: $1,474.1M (+14.0%). More news on: Alexion Pharmaceuticals, Inc., Healthcare stoc… read more...

Alexion Pharmaceuticals beats by $0.20, beats on revenue

via: SeekingAlpha at 2018-02-08 06:32:04:000

Alexion Pharmaceuticals (NASDAQ: ALXN ): Q4 EPS of $1.48 beats by $0.20 . More news on: Alexion Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Alexion Pharmaceuticals beats by $0.20, beats on revenue

via: SeekingAlpha at 2018-02-08 06:32:04:000

Alexion Pharmaceuticals (NASDAQ: ALXN ): Q4 EPS of $1.48 beats by $0.20 . More news on: Alexion Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Alexion Pharmaceuticals beats by $0.20, beats on revenue

via: SeekingAlpha at 2018-02-08 06:32:04:000

Alexion Pharmaceuticals (NASDAQ: ALXN ): Q4 EPS of $1.48 beats by $0.20 . More news on: Alexion Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Alexion Pharmaceuticals beats by $0.20, beats on revenue

via: SeekingAlpha at 2018-02-08 06:32:04:000

Alexion Pharmaceuticals (NASDAQ: ALXN ): Q4 EPS of $1.48 beats by $0.20 . More news on: Alexion Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Alexion Reports Fourth Quarter and Full Year 2017 Results and Provides Financial Guidance for 2018

via: Business Wire at 2018-02-08 06:30:00:000

2017 Total Revenues of $3.551 Billion, a 15 Percent Increase Over 2016 and a 17 Percent Volume Increase 2017 GAAP Diluted EPS of $1.97 Per Share, a 12 Percent Increase Over 2016; Non-GAAP Diluted EPS of $5.86 Per Share, a 27 Percent Increase Over 2016 Continued Double-Digit Volume … read more...

Alexion Reports Fourth Quarter and Full Year 2017 Results and Provides Financial Guidance for 2018

via: Business Wire at 2018-02-08 06:30:00:000

2017 Total Revenues of $3.551 Billion, a 15 Percent Increase Over 2016 and a 17 Percent Volume Increase 2017 GAAP Diluted EPS of $1.97 Per Share, a 12 Percent Increase Over 2016; Non-GAAP Diluted EPS of $5.86 Per Share, a 27 Percent Increase Over 2016 Continued Double-Digit Volume … read more...

Alexion Reports Fourth Quarter and Full Year 2017 Results and Provides Financial Guidance for 2018

via: Business Wire at 2018-02-08 06:30:00:000

2017 Total Revenues of $3.551 Billion, a 15 Percent Increase Over 2016 and a 17 Percent Volume Increase 2017 GAAP Diluted EPS of $1.97 Per Share, a 12 Percent Increase Over 2016; Non-GAAP Diluted EPS of $5.86 Per Share, a 27 Percent Increase Over 2016 Continued Double-Digit Volume … read more...

Alexion Reports Fourth Quarter and Full Year 2017 Results and Provides Financial Guidance for 2018

via: Business Wire at 2018-02-08 06:30:00:000

2017 Total Revenues of $3.551 Billion, a 15 Percent Increase Over 2016 and a 17 Percent Volume Increase 2017 GAAP Diluted EPS of $1.97 Per Share, a 12 Percent Increase Over 2016; Non-GAAP Diluted EPS of $5.86 Per Share, a 27 Percent Increase Over 2016 Continued Double-Digit Volume … read more...

Notable earnings before Thursday's open

via: SeekingAlpha at 2018-02-07 17:30:01:000

ABB , ALNY , ALXN , BCE , BR , BWA , CAH , CBG , CBM , COR , COTY , CVS , EPC , FAF , GLPI , GOOS , GPI , GRA , GRUB , GT , GWR , HBI , K , KKR , LCII , MANU , MAS , MD , MDSO , MLCO , MMS , MMYT , MPW , NJR , NLSN , NS , NYT , ODFL , PAG , PENN , PM… read more...

Notable earnings before Thursday's open

via: SeekingAlpha at 2018-02-07 17:30:01:000

ABB , ALNY , ALXN , BCE , BR , BWA , CAH , CBG , CBM , COR , COTY , CVS , EPC , FAF , GLPI , GOOS , GPI , GRA , GRUB , GT , GWR , HBI , K , KKR , LCII , MANU , MAS , MD , MDSO , MLCO , MMS , MMYT , MPW , NJR , NLSN , NS , NYT , ODFL , PAG , PENN , PM… read more...

Notable earnings before Thursday's open

via: SeekingAlpha at 2018-02-07 17:30:01:000

ABB , ALNY , ALXN , BCE , BR , BWA , CAH , CBG , CBM , COR , COTY , CVS , EPC , FAF , GLPI , GOOS , GPI , GRA , GRUB , GT , GWR , HBI , K , KKR , LCII , MANU , MAS , MD , MDSO , MLCO , MMS , MMYT , MPW , NJR , NLSN , NS , NYT , ODFL , PAG , PENN , PM… read more...

Data Presented at WORLDSymposium(TM) 2018 Show Survival to 3 Years of Age and Improvements in Liver Function in Infants with Lysosomal Acid Lipase Deficiency Treated with Kanuma® (sebelipase alfa)

via: Business Wire at 2018-02-06 19:30:00:000

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the combined interim data from two ongoing open-label studies, VITAL and CL-08, show a 3-year survival estimate of 68% in infants with rapidly progressive lysosomal acid lipase deficiency (LAL-D) treated with Kanuma (sebe… read more...

Data Presented at WORLDSymposium(TM) 2018 Show Survival to 3 Years of Age and Improvements in Liver Function in Infants with Lysosomal Acid Lipase Deficiency Treated with Kanuma® (sebelipase alfa)

via: Business Wire at 2018-02-06 19:30:00:000

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the combined interim data from two ongoing open-label studies, VITAL and CL-08, show a 3-year survival estimate of 68% in infants with rapidly progressive lysosomal acid lipase deficiency (LAL-D) treated with Kanuma (sebe… read more...

Data Presented at WORLDSymposium(TM) 2018 Show Survival to 3 Years of Age and Improvements in Liver Function in Infants with Lysosomal Acid Lipase Deficiency Treated with Kanuma® (sebelipase alfa)

via: Business Wire at 2018-02-06 19:30:00:000

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today that the combined interim data from two ongoing open-label studies, VITAL and CL-08, show a 3-year survival estimate of 68% in infants with rapidly progressive lysosomal acid lipase deficiency (LAL-D) treated with Kanuma (sebe… read more...

Alexion Appoints Judith A. Reinsdorf, J.D., to its Board of Directors

via: Business Wire at 2018-02-05 16:05:00:000

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that Judith A. Reinsdorf, J.D., has been appointed to the Companys Board of Directors.Ms. Reinsdorf is an accomplished executive with a strong background in corporate governance and broad expertise in managing corporat… read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-02-05 06:38:49:000

Dicerna Pharmaceuticals (NASDAQ: DRNA ) initiated with Buy rating and $13 (44% upside) price target at SunTrust. More news on: Dicerna Pharmaceuticals, Inc., AxoGen, Inc., Alexion Pharmaceuticals, Inc., Healthcare stocks news, Read more … read more...

Roche Drifting Ahead Of Key Data

via: SeekingAlpha at 2018-02-02 15:49:13:000

Things arent as dire at Roche ( OTCQX:RHHBY ) as the market may have you believe, but the reality is the company needs to deliver strong clinical data from multiple upcoming late-stage trials. Generics are coming after key drugs that contribute close to 40% of the companys to… read more...

Roche Drifting Ahead Of Key Data

via: SeekingAlpha at 2018-02-02 15:49:13:000

Things arent as dire at Roche ( OTCQX:RHHBY ) as the market may have you believe, but the reality is the company needs to deliver strong clinical data from multiple upcoming late-stage trials. Generics are coming after key drugs that contribute close to 40% of the companys to… read more...

Roche Drifting Ahead Of Key Data

via: SeekingAlpha at 2018-02-02 15:49:13:000

Things arent as dire at Roche ( OTCQX:RHHBY ) as the market may have you believe, but the reality is the company needs to deliver strong clinical data from multiple upcoming late-stage trials. Generics are coming after key drugs that contribute close to 40% of the companys to… read more...

Roche Drifting Ahead Of Key Data

via: SeekingAlpha at 2018-02-02 15:49:13:000

Things arent as dire at Roche ( OTCQX:RHHBY ) as the market may have you believe, but the reality is the company needs to deliver strong clinical data from multiple upcoming late-stage trials. Generics are coming after key drugs that contribute close to 40% of the companys to… read more...

Alexion to Present at the Leerink Partners 7th Annual Global Healthcare Conference

via: Business Wire at 2018-01-31 10:00:00:000

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at the Leerink Partners 7th Annual Global Healthcare Conference in New York City on Wednesday, February 14, 2018 at 11:00 a.m., ET. An audio webcast of the presentation will be available live. You can acc… read more...

Alexion to Present at the Leerink Partners 7th Annual Global Healthcare Conference

via: Business Wire at 2018-01-31 10:00:00:000

Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at the Leerink Partners 7th Annual Global Healthcare Conference in New York City on Wednesday, February 14, 2018 at 11:00 a.m., ET. An audio webcast of the presentation will be available live. You can acc… read more...

Boston's Latest Biotech Arrival Is A Compelling 'Bolt-On' Opportunity

via: SeekingAlpha at 2018-01-29 14:38:10:000

Will 2018 be Alexion Pharmaceuticals (ALXN) annus mirabilis? After a management shakeup, pipeline scare, and mildly disappointing Q3 top line numbers, negative sentiment has clung to like a cheap suit for nearly a year. But there are reasons that suggest that ALXN is a… read more...

Boston's Latest Biotech Arrival Is A Compelling 'Bolt-On' Opportunity

via: SeekingAlpha at 2018-01-29 14:38:10:000

Will 2018 be Alexion Pharmaceuticals (ALXN) annus mirabilis? After a management shakeup, pipeline scare, and mildly disappointing Q3 top line numbers, negative sentiment has clung to like a cheap suit for nearly a year. But there are reasons that suggest that ALXN is a… read more...

Boston's Latest Biotech Arrival Is A Compelling 'Bolt-On' Opportunity

via: SeekingAlpha at 2018-01-29 14:38:10:000

Will 2018 be Alexion Pharmaceuticals (ALXN) annus mirabilis? After a management shakeup, pipeline scare, and mildly disappointing Q3 top line numbers, negative sentiment has clung to like a cheap suit for nearly a year. But there are reasons that suggest that ALXN is a… read more...

Biotech: The Gates Begin To Open

via: SeekingAlpha at 2018-01-26 10:55:19:000

In the 2018 outlook, Biotech Bonanza , published a few weeks ago we had discussed the primary reasons positioning the biotech sector for strong gains this year and noted: We believe 2018 will be a positive year for biotechnology and we will witness record new all-time highs." Biotechno… read more...

Biotech: The Gates Begin To Open

via: SeekingAlpha at 2018-01-26 10:55:19:000

In the 2018 outlook, Biotech Bonanza , published a few weeks ago we had discussed the primary reasons positioning the biotech sector for strong gains this year and noted: We believe 2018 will be a positive year for biotechnology and we will witness record new all-time highs." Biotechno… read more...

Biotech: The Gates Begin To Open

via: SeekingAlpha at 2018-01-26 10:55:19:000

In the 2018 outlook, Biotech Bonanza , published a few weeks ago we had discussed the primary reasons positioning the biotech sector for strong gains this year and noted: We believe 2018 will be a positive year for biotechnology and we will witness record new all-time highs." Biotechno… read more...

Biotech: The Gates Begin To Open

via: SeekingAlpha at 2018-01-26 10:55:19:000

In the 2018 outlook, Biotech Bonanza , published a few weeks ago we had discussed the primary reasons positioning the biotech sector for strong gains this year and noted: We believe 2018 will be a positive year for biotechnology and we will witness record new all-time highs." Biotechno… read more...

Biotech: The Gates Begin To Open

via: SeekingAlpha at 2018-01-26 10:55:19:000

In the 2018 outlook, Biotech Bonanza , published a few weeks ago we had discussed the primary reasons positioning the biotech sector for strong gains this year and noted: We believe 2018 will be a positive year for biotechnology and we will witness record new all-time highs." Biotechno… read more...

Alexion Appoints Deborah Dunsire, M.D. to Its Board of Directors

via: Business Wire at 2018-01-22 16:05:00:000

Dr. Dunsire Brings Deep Biopharmaceutical Experience to Alexions Board Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that Deborah Dunsire, M.D. has been appointed to the Company's Board of Directors as a new independent director. Dr. Dunsire is a proven leader in t… read more...

Alexion to Report Fourth Quarter and Full Year 2017 Results on Thursday, February 8, 2018

via: Business Wire at 2018-01-18 10:00:00:000

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2017 on Thursday, February 8, 2018 before the US financial markets open. Following the release of the financial results, Ale… read more...

Celgene: Parsing Through The $7 Billion Impact Acquisition

via: SeekingAlpha at 2018-01-10 15:01:33:000

Celgene CEO Mark Alles President Trump's tax cuts were expected to usher in a round of share buybacks and acquisitions in the biotechnology space. Celgene ( CELG ) answered the call with its acquisition of Impact Biomedicines for up to $7 billion: Celgene, the acquisitive drugmaker, h… read more...

Alexion Pharmaceuticals (ALXN) Presents At 36th Annual J.P. Morgan Healthcare Conference - Slideshow

via: SeekingAlpha at 2018-01-09 13:32:14:000

The following slide deck was published by Alexion Pharmaceuticals, Inc. in conjunction with this Read more … read more...

Achillion Pharmaceuticals: Ultra-Rare Disease Company With Ultra-Rare Enterprise Value

via: SeekingAlpha at 2018-01-09 11:31:28:000

Background of the Company Achillion ( ACHN ) is a biopharmaceutical company specializing in discovering and developing small molecules for complement-mediated diseases. The complement system is a part of the human innate immune system and is believed to comprise three pathways - the alt… read more...

Omeros Corporation: A Valuation

via: SeekingAlpha at 2018-01-08 13:48:03:000

NOTE: See separate valuation sheet here . Omeros ( OMER ) has had an excellent run this year, gaining nearly 100% as we head into the last two trading weeks for the year. Much of the gains have been driven by the success of OMIDRIA, the companys approved drug candidate. However, … read more...

Valuation Dashboard In Healthcare - New Year's Update

via: SeekingAlpha at 2018-01-08 07:42:50:000

Executive summary Biotechnology is the only Healthcare industry looking underpriced relative to its historical valuation averages, but profitability measured in ROE is below its historical baseline. Healthcare Providers are moderately overpriced (about 20%) and close to their historical ba… read more...

Alexion Pharmaceuticals: A High Conviction, Large Cap Orphan Disease Pick For 2018

via: SeekingAlpha at 2018-01-08 06:45:43:000

We picked up shares of Alexion Pharmaceuticals ( ALXN ) last month. The shares are at a good buy point ahead of several catalysts in 2018. ALXN data by YCharts The stock took a beating after the company announced disappointing Q3 earnings results. Investors also seem to be concerned … read more...

Stocks to watch next week

via: SeekingAlpha at 2018-01-06 09:10:16:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. More news on: Apple Inc., Amazon.com, Inc., Intel Corporation, Tech stocks news, … read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided for free by IEX